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Abstract
Fused in Sacoma (FUS) is a nuclear RNA-binding protein which undergoes liquid-liquid
phase separation (LLPS), and its cytoplasmic aggregation is a pathogenic signature of
amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). It remains
unknown how the FUS-RNA interactions contribute to LLPS and whether its phase
behavior is affected by ALS-linked mutations. By employing combination of single
molecule, biophysical, biochemical and meso-scale tools, we discovered that wild-type
FUS binds single-stranded RNA stoichiometrically in a length-dependent manner
and that multimers induce highly dynamic interactions with RNA, giving rise to
small and fluid condensates. Monomer FUS interacts with the RNA in a well-defined
two-step mode initiated by its RNA binding domain (RBD), more specifically the
RNA recognition motive (RRM) to form a proper FUS-RNA complex. This proper
complex formation dictates the properties of multimer FUS-RNA interaction and phase
separation. In contrast to the wild-type, ALS-linked FUS mutations in arginine display
a severely altered and static binding to RNA, and formation of large condensates,
signifying the role of arginine in driving proper RNA interaction. Glycine mutations
undergo rapid loss of fluidity, emphasizing the role of glycine in promoting fluidity.
Strikingly, the nuclear import receptor, Karyopherin-β2 reverses the mutant defects
and recovers the wild-type FUS behavior. We reveal two distinct classes of ALS-linked
FUS mutants underpinning potentially disparate pathogenic mechanisms.
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Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic lateral sclerosis (ALS) is a fatal, progressive, and age-dependent neu-
rodegenerative disease targeting motor neurons. "Amyotrophic" refers to the weakness
and muscle atrophy in lower motor neurons. "Lateral Sclerosis" is the hardness to
the lateral columns of the spinal cords in autopsy specimens [1]. This disease is also
commonly known as the Lou Gehrig’s disease after the famous American baseball
player who died from ALS. The incidence and prevalence rate of ALS has been reported
to be 0.4-2.4 and 1.5-7 per 100,000 people, respectively [2]. Among all ALS cases,
about 90% are genetic but without any obvious family history (sporadic cases) and
the remaining 10% of cases are inherited (familial cases) [1–3]. Although the disease
usually onsets later in adulthood (average onset age of 55 years), the symptoms could
appear in the early decades of a patient’s life.
In 1993, mutations in SOD1 were reported to be associated with familial ALS for
the first time [4]. To date, many more genes and mutations have been identified as
ALS-linked. The most common ALS-associated genes are C9ORF72 [5], TARDBP
which codes for TDP-43 [6], FUS [7], UBQLN2 [8]. These genes are only responsible
for less than half of all ALS cases. Autopsies exhibit degeneration of neuron in the
motor cortex of the brain and the anterior horns of the spinal cord. As the spinal
1
motor neurons degenerates, the muscles under their control lose their effectiveness
and eventually atrophy. Further progression of the disease leads to the formation of
rounded or fibrous protein aggregates start to form which are referred to as inclusion
bodies resulting in the death of the neuron cell [9]. However, the exact pathology for
each case is slightly different and in some cases not fully understood.
Understanding biological condensates
Membrane-less organelles
Eukaryotic cells are complex machines that execute many processes to sustain the life
and function of each cell. This is not possible without a high level of organization and
compartmentalization of cellular content and biochemical functions [10, 11]. Many
of these compartments, which are also called organelles, are physically separated
from their environment via a membrane which serves as a physical barrier; examples
include as the nucleus, mitochondria, the Golgi apparatus, and many more. Distinct
composition of such organelles are strictly regulated by controlling their pores and
channels. Recent studies revealed that there are abundant presence of universally
conserved membrane-less bodies carrying various cellular functions that lack the
traditional physical boundaries. Membrane-less bodies can easily form and disassemble
with different molecular cues depending on the role they play [12–14].
These membrane-less bodies are present both in the nucleus and the cytoplasm. In the
nucleus, there are nucleoli [15–17], nuclear speckles [18], paraspekles [19], and Cajal
bodies [20, 21]. The nucleolus is formed within the nucleus and is mainly responsible
for the production of ribosomal RNAs and assembly of the ribosomal units. Nuclear
speckles are bodies that are enriched with pre-mRNA splicing factors in the nucleus.
Paraspekles contain long non-coding RNA transcript of NEAT1 which responds to
stress conditions [22]. Cajal bodies are responsible for modifying small nuclear RNAs
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and assembly of related ribonucleoproteins (RNPs) [20].
The cytosol harbors various membrane-less bodies such as P granules [12, 23], stress
granules [24, 25], and processing bodies (PB) [26, 27]. P granules are mainly observed
in C. elegans as their germ granules having a critical role in proper embryogenesis.
Stress granules (SG) are membrane-less bodies that form when the cell is under variety
of stress conditions. They harbor a wide range of mRNAs that are stalled during
translation due to stress and different proteins that are recruited to protect these
RNAs. Lastly, processing bodies are foci in the cytoplasm playing an important role
in different mRNA decay pathways and microRNA induced mRNA silencing.
Studies have shown that these membrane-less organelles are formed through the
process of liquid-liquid phase separation (LLPS) in which the constituents condense
within their aqueous environment [12, 28–30]. The physical theories pertaining to
LLPS has been established for many year, however, it has become more studied
for biological systems in the past decades. These bodies are termed "biomolecular
condensates" forming through LLPS and their material properties resemble liquids or
gels [28, 31]. To understand this phenomenon further, following sections will discuss
the concepts of liquids and phase separation in more detail.
Liquid and phase separation
Liquid is a state of matter in which the atoms and molecules are in close proximity
compacted similar to a solid but can also diffuse very rapidly and exchange. This is
the key property that defines liquids and all the other properties that are expected of
liquids. For examples, liquids do not have an inherent shape and take the shape of
their containers. They also do not have a memory of their previous shape. In other
words, if liquids are transferred from one container to another, they do not have any
reminiscence of their previous shape and immediately take the shape of their new
container. Moreover, the interface of liquids with other forms of matter is governed
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by their surface tension, giving rise to liquids continuous interface. What if there is
no container like a drop of water in an isolated space with no gravity? In this case,
liquids are forced to take a spherical shape dictated by the laws of thermodynamics.
Systems will equilibrate to their lowest energy state. For our isolated liquid droplet,
the surface tension is unfavorable in terms of energy, therefore, the liquid needs to
minimize its surface tension. Among all shapes, sphere has the lowest surface energy,
hence, a drop of liquid without a container will take a spherical shape.
Another property of both simple and complex liquids is their viscosity. Since molecules
in a liquid can rearrange very easily, plasticity is not applicable instead they have
viscosity which is a measure of how it reacts to shear forces. When pouring syrup, it
flows slower than water because it is more viscous. Another key property is fusion
which directly reflects the viscosity of the liquid. Picture two drops of water; when
brought close to one another. These drops can fuse into each other and make one larger
drop to reduce the system’s energy by reducing the total surface. Mathematically, the
area sum of two spheres is larger than the surface area of the merged sphere; hence, it
is more favorable to fuse than stay separated. However, the rate that droplets fuse
is inversely proportional to their viscosity meaning that the less viscous the liquid,
the faster droplets fuse [32]. Experimental techniques like fluorescent recovery after
photobleaching (FRAP), microrheology, and droplet fusion using optical tweezers
enables scientists to study mentioned above material properties of biological liquid
droplets.
Knowing the properties of liquids help understanding the underlying mechanism
of phase separation. Thermodynamically, systems go towards reducing their overall
energy state untill they are stabilized at their lowest energy state. One typical example
is mixing water and oil. When water is added to water, it fully mixes; when oil is
added to oil, it also fully mixes or it is miscible. But why water and oil do not mix?
Water molecules clustered together will have an energy of ∆Gw and oil molecules
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clustered will have ∆Go. When these components are mixed the energy of the system
will become ∆Gw+o. Since in this special case ∆Gw+o > ∆Gw + ∆Go, it is more
energetically favorable for oil and water to stay separated that mixed together giving
rise to oil phase separating in water.
Figure 1-1. Schematic showing the free energy of water and oil mixing.
Similar to membrane-bound organelles, membrane-less bodies need to (a) exchange
materials inside the compartment and with their environment and (b) stay phase
separated from the surrounding cytosol or nucleoplasm to sustain themselves. As for (a),
this stochastic movement of molecules in an environment is called diffusion, which for
liquids is quantified by a diffusion constant inversely correlated to viscosity. Diffusion
is necessary for maintaining the flux of materials in and out of the condensate or
redistribution of materials inside the bodies for many chemical and biological reactions.
The driving force for diffusion is the difference in chemical potential between inside
and outside of the condensate or different parts of it. Moreover, the capability to
phase separate and stay separated from the surrounding gives these compartments
their unique functions. For example, phase separation allows these compartments to
rapidly increase the local concentration of certain proteins or metabolites allowing
the cells to perform a function. For instance, when the kinase DYRK3 is inactive it
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gets recruited to the SGs and prevents the release of mTORC1. But when DYRK3 is
activated, it can dissolve SGs and release mTORC1 [33].
Molecular drivers of phase separation in biological systems
In the cells, phase separated bodies are composed of many components but it is
possible to reduce these systems in vitro to study the phase separation of one protein
or few components in conjunction. Many of these components have weak interaction
domains that repeat throughout the protein, and these interacting domains may be
sufficient to drive phase separation [34, 35]. A large portion of proteins incorporated
in granules have disordered regions which means they do not form stably structured
conformation. This disordered property arises from the sequence of these proteins
which exhibits a strong bias towards certain amino acids [36]. These amino acids shift
the equilibrium to more unstructured state with many conformational possibilities.
Proteins that have these regions are called intrinsically disordered proteins (IDPs) and
are characterized by their low-complexity domains, having a small subset of amino
acids present in their sequence [37]: 1) polar residues like glycine (G), glutamine (Q),
asparagine (N), and serine (S); 2) positively charged residues such as arginine (R)
and lysine (K); 3) negatively charged residues like aspartic acid (D) and glutamic
acid (E); 4) aromatic amino acids such as phenylalanine (F) and tyrosine (Y) [38].
The disordered regions of many peptides are composed of repeats of combinations of
these amino acids. But what are the forces in the protein that contribute in phase
separation of these proteins? How do these proteins interact with one another?
There are four different interaction forces that contribute to LLPS ordered from most
salt dependent to least salt dependent:
1. Charge-charge: is when two charged residues interact with one another. It
could be attraction between opposite charges or repulsion between similarly
charged residues.
6
2. Cation-π: is a non-covalent interaction between a cation with the face of an
electron rich system such as aromatic rings that have charge distributions on all
over the ring. This interaction is effective in shorter ranges and is directional.
3. Dipole-Dipole: is a type of intermolecular force that occurs between two dipoles.
It has important roles in the both secondary and tertiary structures of proteins.
4. π-π stacking: is the interaction between two aromatic resides which happens
by stacking the aromatic rings. These stacking interactions are also seen in DNA
and RNA structures between different bases. These interaction and very short
range and directional.
Proteins as polymer chains: stickers and spacers
Many studies have shown that disordered proteins can phase separate in the cellular
context and in vitro behaving like polymer chains which we discussed so far. But is it
possible to use existing knowledge from polymer physics to model and understand
these biocondenstates? Since proteins are more complex than homopolymers having
precise chemical properties per residue and varying distribution of charges, normal
theories do not easily apply. Instead, proteins are counted as "macromolecules with
attractive groups" which can interact through different forces mentioned earlier [39,
40]. Similar to simpler polymers, the interaction between these molecules can be
explained with the spacer and sticker model. Stickers are regions of the polymer chain
that attract other molecules and form intermolecular connections through reversible
non-covalent bonds. Spacers, by contrast, are regions that intersperse the stickers and
don’t play a significant role in interactions. In biological proteins, the biochemical
properties of various residues determine if they are stickers or spacers. In disordered
proteins, stickers are usually short stretches while spacers are longer regions flanking
the stickers. In some cases, sticker regions may also be folded binding domains of the
7
protein and the spacers be the disordered linkers.
Stickers and the spacers can be identified computationally or experimentally. When
done computationally the model should take into account loss of the sticker should
impact the Csat, concentration at which the system starts to phase separate, and the
spacer shouldn’t. Experimentally, a full mutagenesis of all residues are needed to
reach a reasonable conclusion.
Dynamics of phase separation
Previous sections have focused on why LLPS is important and beneficial for the
eukaryotic cell; in the section, the nucleation of phase separated condensates will be
discussed in more detail.
Nucleation can occur in two very different forms: homogeneous or heterogeneous. In
the case of homogeneous nucleation, molecules come together stochastically with the
correct configuration and form a nucleus. This process is very rare[41, 42]. A more
likely scenario is nucleation through preformed structures which is called heterogeneous
nucleation [43]. For instance, phase separated bodies can form around preexisting
structures like preformed rRNA complexes in the nucleolus [44]. But now that the
droplet has been formed, how does it grow and how is the size of the droplet controlled?
From an energetic point of view, a nucleated phase can only grow when the added
molecules decrease the free energy of the system. There are various mechanisms that
a phase can grow and further separate from its surrounding, including recruitment
of more proteins or RNP complexes to the nucleated site, condensate fusion, and
Ostwald ripening. The first two processes have been previously discussed, but Ostwald
ripening is the process in which a smaller droplet when in proximity of a larger droplet
shrinks and the components of it transfers to the larger droplet [45]. This is driven by
different chemical potentials between droplets of different sizes resulting from different
inside/outside pressure differences, also known as Laplace pressure. Smaller droplets
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have larger Laplace pressure, therefore, higher chemical potential causing a transport
of materials from smaller to larger droplets. The droplet size can also be controlled
in several ways. One way is to regulate or prevent fusion or coalescence to happen.
For example, in nucleoli, actomyosin mesh network stops fusion and regulates the
size of the nucleolus due to its small mesh size in comparison to the nucleolus [46].
Another mechanism is the surface effect in stabilizing the size of the formed droplet. A
common example is the addition of surfactants in oil-water emulsion. Finally, external
regulatory components or chemicals can control the size of the droplets [47].
Fused in sarcoma (FUS)
As we discussed earlier in this chapter, many disordered proteins undergo LLPS that
are known to be associated with ALS, leading to aggregation when mutated. One of
these proteins is Fused in sarcoma (FUS) that undergoes LLPS through its extensive
disordered regions, and mutations in FUS are causative in a portion of ALS/FTLD
patients [48–53]. FUS was found about 23 years ago as a fusion oncogene in human
myxoid liposarcoma, which is a type of tumor tissue in human cells especially fat
cells [54–56]. FUS is a nuclear RNA binding protein that shuttles in and out of the
nucleus [57, 58] encoded by the FUS gene located on position p11.2 of chromosome
16. It is critical for several RNA metabolism events such as transcription [56, 59],
microRNA processing [60–62], and mRNA splicing [63, 64]. For example, Morlado et
al. [61] showed that FUS is recruited to chromatin at the transcription site and binds
to pre-microRNAs playing a role in its biogenesis. They also show that depleting FUS
will result in depleted Drosha in the same loci suggesting that FUS indeed regulates
the biogenesis of a subset of microRNAs. Besides its RNA processing roles in the
nucleus, FUS also colocalizes with ribonucleoprotein (RNP) bodies such as stress
granules (SGs) in the cytoplasm [25, 65].
FUS is a highly disordered protein that drives LLPS by its low complexity domain
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Figure 1-2. Disorder map of WT FUS
(LCD) and RNA binding domain (RBD) [25, 30, 43, 65–67]. The length of the protein
can be divided into multiple domains as shown in Figure 1-2: the N-terminal LCD
which is also known as the prion-like domain (PrLD) [54]; three RGG domains which
are enriched in arginine and glycine; an RNA recognition motif (RRM); a Zinc finger
domain (ZnF); and a nuclear localization signal (NLS) at the C-terminus. For the
purposes of this thesis, FUS can be bisected into two halves: LCD and the RNA
binding domain (RBD). A more careful examination of the domain map shows that
FUS is highly asymmetric. The N-terminus of the protein (LCD region) is almost
exclusively disordered whereas the C-terminus consist of highly ordered regions flanked
by disordered patches. In terms of composition, LCD and RBD are highly asymmetric
as well. LCD mainly contains a small subset of amino acids such as glutamine (Q),
serine (S), glycine (G) and enriched in aromatic residues like tyrosine (Y) [68–70]. On
the contrary, RBD is consist of highly order regions separated by disordered patches
(RGG domains) which is also enriched in charged residues like arginine (R) and glycine
(G)[71].
In accordance with the theoretical work done on stickers and spacers discussed
earlier, a study by Wang et al. [71] has done a systematic substitution analysis of
important residues for FUS to come up with classification of sticker and spacer residues.
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The substitution of all the arginines (R) and tyrosines (Y) resulted in dramatically
increasing the Csat (concentration required for LLPS) of FUS from 2.5µM for over
100µM. In contrast, mutating all the glycines (G), serines (S), or glutamines (Q)
didn’t impact Csat of FUS while they altered the fluidity of the phase separated FUS
condensates (G mutation decreased, S and Q mutations increased fluidity). Given
these observations and the theoretical knowledge in the literature, they concluded
that R and Y are sticker residues of FUS whereas S, Q, and G are spacer residues.
FUS phase separation
The majority of LLPS research has focused on the role of proteins or subdomains of
disordered portion of proteins alone. But a closer look reveals that many of these
proteins are RNA binding proteins (RBPs) with high affinities for RNA and known
fuction in RNA metabolism. Therefore, it is important to understand how RNA
contributes to and modulates LLPS. Literature suggests that RNA plays a critical
role in seeding and nucleating RNP granules [32, 72, 73]. We and others also have
reported that RNA can alter the in vitro viscoelastic properties of different RNA-
binding proteins such as Whi3 and LAF-1 [32, 74]. For example, earlier work on
Whi3 demonstrated that RNA structure is critical in establishing granule identity,
and the RNA-protein interaction tunes the condensate property [74]. Such studies
highlight the importance of RNA, yet little is known about the impact of RNA in
FUS condensation. How does RNA play its role in forming droplets in complex with
the highly disordered proteins like FUS?
Both proteins and RNAs are considered to be biopolymers that undergo phase separa-
tion. As mentioned earlier in the chapter, disordered proteins can go through LLPS
via self-association, π-π interaction, π-cation interaction, or charge-charge interactions.
But, given the poly-anionic nature of the RNA, charged interactions between the RNA
and proteins and increased multivalancy can favor droplet formation [75, 76]. RNA
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sequence, structure, and length can also control LLPS condensate formation and its
biophysical properties.
Some RNA-binding proteins have specific sequence motifs to bind but majority are
not. As an example, Whi3 binds to (U)GCAU motif in mRNA [77] whereas FUS is a
more promiscuous RNA binding protein with slightly higher preference for U and G
rich sequences [78]. The single-stranded nature of RNA allows it to stabilize in unique
structures compared to DNA and bind to variety of proteins. A great example is
messenger RNA (mRNA). Some mRNAs are encoded with structured regions reducing
the degradation of the RNA and unstructured sections that can engage in interactions
[79]. Salt concentration can stabilize RNP interactions both in vitro and in vivo by
controlling the charge-charge interactions. Physiological concentrations of RNA are
both high enough to seed LLPS but also low enough to confer selectivity on RNA-RBP
interactions [80, 81]. The length of the RNA controls valency level of the RNA and
tune RBP-RNA interaction and the properties of the formed droplet [82, 83]. We
demonstrated the relation between the length of the RNA and degree of dynamic
vs. static RNA interaction induced by FUS [82]. Shorter RNA can harbor less FUS
proteins, therefore, static interaction is dominant. But, when the length increases,
more FUS can bind and shift the nature of the interaction to being dynamic.
Given FUS’s role in RNA processes, it is evident that its RNA binding ability and
RNA binding mode is important for its function and LLPS. RNA can also control the
phase-separated condensate’s properties. As shown earlier, FUS can form droplets
without RNA but RNA could seed FUS droplets at lower concentrations and nucleate
higher order RNP complexes. Shwartz et al. show that RNA can seed the droplet
formation by acting as a scaffold harboring multiple FUS proteins [78]. Multiple
FUS can bind to RNA with great cooperativity nucleating higher order FUS-RNA
complexes. They also observe that full binding cooperativity requires both the RBD
and the RGG domain. Multivalency of the RNA could also help form FUS droplets at
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concentrations lower than its normal physiological concentrations [82, 84]. Besides
RNA sequence and structure, the RNA-to-protein concentration ratio is also critical
in regulating the formation of FUS droplets. Maharana et al. studied the RNA ratio
effect in vitro and in cells [85]. They hypothesized that RNA buffers phase separation
of FUS like proteins i.e higher RNA to protein concentration ratio in the nucleus than
the cytoplasm is responsible for diffuse pattern of in the nucleus and FUS condensates
in the cytoplasm. To test their hypothesis, they formed droplets in vitro and titrated
varying concentrations of RNAs, showing that higher RNA concentrations, caused the
droplets to disappear. To examine this change in vivo, they injected RNaseA into the
nucleus and observed instantaneous appearance of FUS condensates.
Altogether, these studies suggest that RNA has the ability to regulate the phase
separation of different RBPs, especially FUS, potentially by engaging is charge-charge
and multivalent interactions with the protein. However, the molecular fundamentals
of these interactions are not well understood. We tried to address this issue and close
the knowledge gap in this work.
ALS-linked mutations in FUS
Many studies have investigated the effect of FUS mutations and their role in ALS [86,
87]. About 1% of ALS patients and 9% of FTD patients show some genetic mutation
of FUS [88]. Numerous ALS/FTD-associated mutations in FUS are clustered in the
IDR and the NLS domain [84, 89–91]. The exact nature of FUS pathology and toxicity
is not well understood but given its functional roles, cells RNA homeostasis could
be affected. There is evidence suggesting that both loss and gain of function cause
toxicity in patients [92]. More than 70 FUS mutations have been linked to ALS, of
which the majority are arginine and glycine mutations [86]. These residues are known
to be the sticker and spacer residues in FUS and are spread throughout the disordered
domains of the protein [71]. A significant number of these mutations are located at
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Figure 1-3. A map of ALS-linked mutations of FUS
the nuclear localization signal (NLS) of the protein [86, 93, 94], in agreement with the
mis-localization FUS as a potential pathogenic defect.
The NLS of FUS is identified as the PY-NLS type based on the presence of Pro508-
Tyr526 (sequence: PGKMDSRGEHRQDRRERPY) [95]. The PY-NLS is recognized
by a protein called Importin-1 or Kapβ2 that is responsible for shuttling FUS back to
the nucleus [96]. Scekic-Zahirovic et al. [97] deleted the NLS domain of FUS in mice
and observed that the protein mis-localized to the cytoplasm which was toxic. They
also showed that this toxicity is due to the gain of function from the mutant. This
unusual increase in cytoplasmic FUS compared to the RNA accelerates aggregation
and increased toxicity in the cells [85]. Another common FUS mutation is R495X
(missing amino acids from 495-526, which includes the NLS) which is also known to
cause mis-localization in the cytoplasm leading to disease [98]. An example of a severe
mis-localized FUS mutation is P525L which has an early onset age in patients [96,
99]. Studies show that Kapβ2 is unable to recognize FUS-P525L mutant, therefore,
it aggregates in the cytoplasm. Other than mutations that directly impair Kapβ2
recognition, there are several other prevalent NLS mutations such as R521C/G/H,
R524S, R522G, R518K, H517Q, and G515X [7, 99–101]. These mutations tend to
form punctae in the cytoplasm when the cell undergoes stressed conditions.
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Besides the NLS mutations, there are many FUS mutations that are located in the LCD
and RGG domains. Some of the most well-described patient-occurring mutations are
G156E, R244C, P106L, G225V, and R216C [94, 96, 102]. For example, Nomura et al.
[94] showed that G156E exhibits higher aggregation propensity and seeds aggregates
in vitro. This mutation can form inclusion bodies in vivo inside the nucleus since its
NLS domain is intact. In contrast, the same group examined G225V and observed
that this mutation neither forms inclusion bodies nor has high aggregation propensity.
We observed similar results in the presence of RNA. However, they reported that
common feature between these two mutations is the accelerated aging and loss of
condensate fluidity consistent with the sticker and spacer model [71]. Other in vitro
studies on R244C and R216 show that both of these mutations have altered RNA
interaction and form large droplets with low fluidity. Both of these point mutations
are heavily aggregated and very toxic for the cells.
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In the coming chapters ...
This thesis will focus on understanding how FUS-RNA complexes form and dissolve in
a more mechanistic and molecular approach. To study this topic in a more systematic
manner, we established a framework in which we investigated assembly steps of FUS
condensates from a single RNA and single FUS protein all the way to droplet forming
conditions. In Chapter 2, we characterized how wild-type(WT) FUS interacts with
RNA using our framework as the road-map. In Chapter 2, we studied the full-length
WT and how it forms phase separated bodies in the presence of RNA as a baseline for
the normal phenotype of FUS. We observed that WT forms an RNP complexeses in a
very well-defined manner that includes dynamic interactions with RNA. This gives
rise to small droplets with high fluidity. Having established the WT as the reference,
we then tried to understand how each domain in the full length protein drives different
RNA interaction patterns in the second half of Chapter 2. We concluded that the
RNA binding ability of FUS and proper formation of these RNP complexes is crucial
for its RNA interaction patterns.
After establishing how the WT FUS interacts with RNA, we next moved to ALS-
linked mutants in Chapter 3, investigating how they differ with WT FUS and if
their phenotypes can be reversed. Using our described framework from Chapter 2,
we characterized the RNA interactions of ALS-linked FUS mutations compared to
the WT in Section 3. We found that two distinct classes of mutations (arginine and
glycine mutations) that could be clustered based on their condensate properties and
RNA interaction phenotypes. This result implies that ther might be different disease
pathways for different mutations. Potential therapeutic approaches were also explored
by attempting to disaggregate these disease-linked FUS mutants discussed in the later





Fused in sarcoma (FUS) is an RNA-binding protein (RBP) involved in a variety of
RNA metabolic processes and the formation of ribonucleoprotein (RNP) bodies such as
stress granules (SGs) [25, 65]. RNP bodies are proposed to form by liquid-liquid phase
separation (LLPS), driven by transient multivalent interactions between RNA and
RBPs containing intrinsically disordered regions (IDRs) and RNA recognition motifs
(RRMs) [30, 66, 67]. Previous studies have focused primarily on protein-only systems
and neglected the role of RNA and RNA-protein interactions in phase separation.
However, the emerging view acknowledges a cooperative effect of RNA-RNA [73, 103],
RNA-protein, and protein-protein interactions in RNP granule assembly and disease
progression. RNA can seed FUS droplets by increasing multivalent interactions [78,
89, 91].
In mammalian cells, RNA buffers phase separation of FUS and RBPs; the high
RNA-to-protein ratio in the nucleus keeps RBPs soluble, whereas the low ratio in
the cytoplasm promotes condensation [71]. In fact, the RNA-binding ability of
ALS mutant FUS is what allows the protein to localize to SGs, where it exhibits a
neurodegenerative phenotype [104], reinforcing the role of RNA in granule formation
and disease onset. Nevertheless, a fundamental molecular-level understanding of how
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the initial interaction of RNA and IDR proteins affects LLPS and drives the disease
phenotype is lacking. In this chapter, we address this gap by directly probing RNA
interactions with FUS, one of the major proteins implicated in ALS/FTD.
Figure 2-1. Flowchart showing FUS-RNA droplet formation steps from single molecules
to phase separated bodies
In this chapter we will focus mainly on WT FUS and its RNA interaction. Figure 2-1
depicts the path FUS-RNA takes to become a phase from a single protein interacting
with a single RNA molecule. FUS and RNA come together to form different RNP
complexes to nucleate a droplet. Given the right conditions, these RNPs grow and
form phase separated bodies with unique biophysical properties. Characterizing the
RNA binding mode of WT FUS will create a baseline against which to compare
ALS-linked FUS variants. This baseline enables us to answer three critical question;
(1) How do different portions of WT FUS contribute to its overall RNA interaction?,
(2) How do mutations differ in RNA interactions compared to the WT?, and (3) When
does the mutation become aberrant?.
Understanding WT FUS as a reference
WT FUS interacts with RNA dynamically
To study the single FUS-RNA interaction, we used single molecule FRET (smFRET).
FUS is known to be bind to RNA promiscuously with a preference for single-stranded
RNA (ssRNA) [105, 106]. Therefore, we used a 50-nt polyU partially duplexed RNA
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(pdU50), prepared as described in the method section (Sec 4), with Cy3 and Cy5
dyes as FRET pairs [107]. The RNA labeling and experimental scheme is shown in
Fig 2-2A. We chose an unstructured homopolymer RNA to eliminate the effect of
structure on FUS-RNA interaction. After immobilizing the RNA on the surface of
a quartz PEG slide, the RNA only yielded a steady low FRET efficiency of 0.2 (Fig
2-2B). Upon addition of 5nM WT FUS, the histogram shifts form low FRET (0.2)
to high FRET (∼0.8). Time traces show that FUS interacts with RNA in a static
manner. This suggests that the protein brings the two ends of the RNA close to one
another stably upon binding exhibiting a tight and compact binding.
Figure 2-2. (A) Schematic of the smFRET experiment in which Cy3 and Cy5 attached to
either end of U50 RNA report on the conformational change induced by FUS binding.(B)
smFRET representative traces and histograms for increasing FUS concentrations (0–500nM)
and after buffer wash of free protein in solution.
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As FUS concentration increases (50–500 nM), the high FRET population diminishes
and is replaced by a mid FRET population (∼0.5) associated with dynamic fluctuations
based on the time traces in Fig 2-2B. The proportion of these dynamic traces increase
as FUS concentration increases to a point that more than 90% of all molecules display
a fully dynamic trace for concentrations greater than 200nM. To explain these dynamic
fluctuations, there are two possible scenarios (Fig 2-3): 1) binding and unbinding of a
second unit and 2) due to the dynamic conformational change of RNA induced by
multiple units of continuously bound FUS molecules. Each of these scenarios have
associated predictions which are shown in detailed in Figure 2-3.
Scenario 1 predicts:
• FRET fluctuation will speed up as a function of FUS concentration (the binding
frequency will increase WT FUS concentration)
• The dwell times collected from FRET traces (2-4) will show varying kinetics
• EMSA will equilibrate to half in singly bound (C1) and half in two-bound (C2)
states at high FUS concentration
However, scenario 2 predicts:
• FRET fluctuations will occur in bursts or clusters and the cluster size/duration
will grow as a function of FUS concentration
• Dwell times measured in Figure 2-4 will be independent of FUS concentration
• EMSA will shift toward two-bound (C2) state at higher FUS concentrations
To test these hypotheses, we measured the time between each consecutive FRET
fluctuation (δt) plotted it for increasing concentrations of FUS. Then, we fitted
the data using a single exponential decay and extracted the rate constant (τ) at
each concentration. As shown in Figure 2-4, τ stays constant over concentration
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Figure 2-3. Two possible scenarios explaining WT FUS dynamic interactions observed in
smFRET traces
suggesting that scenario 2 is likely to be correct and these fluctuations do not arise
from binding/unbinding of the WT FUS.
Complex 2 drives dynamic RNA interactions
After establishing the presence of two different populations (static high FRET and
dynamic mid FRET), we wanted to characterize the stoichiometry of each population.
To do so, we ran an EMSA (Figure 2-5)using the same RNA constructs as in our
single molecule assays. At lower concentrations of FUS (∼10nM) there is a single shift
observed from the RNA band which we called complex 1 (C1). As the concentration
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Figure 2-4. Dwell time analysis of the dynamic FRET fluctuations at 50, 100, and 500
nM FUS fitted with a single-component exponential decay, with the bar graph representing
the mean and SD of the fitted decay time.
exceeds 50nM, a second supershifted band appears, complex 2 (C2), which becomes
dominant at concentrations greater than 100nM. The EMSA pattern observed here
closely resembles the predicted EMSA for scenario 2 shown in Figure 2-3. Interestingly,
the observed fraction of complex 2 in EMSA is highly correlated with the fraction
observed dynamic in each smFRET trace from Fig 2-2B over varying concentrations;
the more C2 the more dynamic FUS-RNA interaction is observed at the single molecule
level. Altogether, this suggest that C2 is the dynamic interactions arise from the
presence of complex 2 (C2). But some questions remain unanswered; what is the
stoichiometric state of C1 and C2? Are these complexes monomer-dimer?
Complex 1 and 2 are monomer and dimer
To answer more detailed questions about C1 and C2, we used FUS tagged with
a C-terminal EGFP and purified the whole construct to perform photobleaching
experiments. We immobilized the same pdU50 RNA construct but with only Cy5 label.
This was done mainly for localization purposes while preventing Cy3 crosstalk with
GFP. Next, varying concentrations of FUS::GFP was introduced to the RNA, as shown
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Figure 2-5. (A) EMSA gel using pdU50 RNA (1 nM) at increasing FUS concentrations
(0–500 nM). The arrows indicate bands representing RNA alone, complex 1 (C1), and
complex 2 (C2).(B) Correlation plot (R2 = 0.95) between the fraction of C2 observed in
the EMSA and the fraction of dynamic FRET traces at different FUS concentrations. The
error bars represent STD.
in Figure 2-6A, the FUS::GFP was bleached by a high power laser at λ = 488nm, and
the photobleaching steps were counted (Fig 2-6B). Since photobleacing is a stochastic
phenomenon, the number of steps reveals the number of bound molecules to the
RNA. Because of the high fluorescence background, we could not take measurements
above a concentration of 50nM FUS::GFP. As quantification in Figure 2-6C reveals
single-step bleaching is mostly observed at lower concentrations (2.5-10nM). In this
concentration range the molecules are mainly in the C1 regime and exhibit high
FRET static RNA interaction (Fig 2-2B). As the concentration increases, the two-step
bleaching population increases such that about 15% of all molecules at 50nM show
two-step photobleaching. These concentration ranges align with the appearance of C2
(Fig 2-5A) and mid FRET dynamic traces. In addition, as a control, we confirmed
that the FUS::GFP construct displays the same RNA interaction pattern as FUS-WT
(Fig 2-7A). GFP can auto-dimerize [108], so to address this issue and increase the
accuracy of our measurements, we immobilized 5nM of FUS::EGFP using an anti-GFP
antibody and performed the same photobleaching experiment. The data shows that
∼30% of the molecules form dimers (Fig 2-7B and C) which we used to subtract as
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Figure 2-6. (A) FUS::EGFP experimental scheme used to count photobleaching steps
determining the stoichiometry of RNA:FUS at varying FUS conditions. (B) Representative
single-molecule trace of one-step and two-step photobleaching. Arrows indicate individual
photobleaching steps. (C) EGFP photobleaching counts for different FUS concentrations
after subtracting the inherent dimerization because of EGFP alone
background for Figure 2-6C.
Taken together, C1 represents a FUS monomer interacting stably with ssRNA,
yielding a steady high FRET signal, whereas C2 is likely two units of FUS engaging
weakly with RNA, establishing highly dynamic interactions.
RNA length controls FUS multivalency
pdU50The previous experiments used RNA of only one length, pdU50. We next asked
whether the length of the RNA controls the valency for FUS binding. To further
test this, we made partially duplexed RNA constructs with varying polyU lengths,
Figure 2-7. (A) WT FUS::GFP smFRET representative trace with pdU50 RNA at 5, 50,
and 500nM. (B,C) EGFP photobleaching of 5nM WT FUS::GFP alone immobilized on the
surface using anti-GFP antibody. (C) Bar graph showing bleaching step quantification for
EGFP alone. Data is represented as mean ± SEM.
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from 10-70 nucleotides. Figure 2-8A (left panel) shows all the Cy3 labeled ssRNAs
on a native gel. As expected, the band position for each RNA shifts upwards as the
length increases confirming that the RNAs used are indeed of varying lengths. We
next annealed the ssRNAs to a Cy5 18-mer strand (methods section 4) and the native
gel displays a clear separation of both the single-stranded and the partially duplexed
RNA bands (Fig 2-8A right panel) demonstrating that strands were annealed.
To check the stoichiometric states of FUS with varying lengths of RNA, we performed
EMSA with theses constructs at 0,5, 50, and 500nM WT FUS concentrations (Fig
2-8B). At smaller sizes (pdU10-pdU30) complex 1 is the only complex present complex
regardless of the concentration (Fig 2-8B, top panel). The FUS-pdU40 shows a faint
population of C2 at higher concentration whereas pdU50 exhibits a dominant C2
band at the same concentrations. The longer pdU70 RNA displays C1, C2, and an
additional supershifted band that we called complex 3 (C3) at higher concentrations.
Together with the data presented in Figure 2-5 and Figure 2-6C, the presence of C3
strongly suggests that C1, C2, and C3 are monomers, dimers, and trimers of FUS
bound to RNA, respectively. It is noteworthy that despite the differences in molecular
weight of RNA substrates (Fig 2-8A all C1 and C2 FUS-RNA complexes show the
same mobility shift in EMSA gels, indicating extensive contact between RNA and
protein that results in similar hydrodynamic radii for all RNP complexes containing
varying lengths of RNA.
These constructs were individually tested in our smFRET assay. Figure 2-8C displays
the results for pdU10-50. Upon addition of FUS-WT (500nM), the FRET peaks
shifted from lower values (Fig 2-8C, light gray histograms) to higher values (Fig
2-8C, dark blue histograms) confirming that FUS can bind to all RNA lengths used
in this experiment. Comparing the peak location of gray histograms at different
concentrations reveals that increasing the length of the RNA, which increases the
distance between the acceptor and donor FRET pair, shifts the peak to lower values,
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as expected. FUS binding to pdU10–pdU30 produced a sharp high FRET peak with
corresponding static high FRET traces. For pdU40, the static high FRET trace
is interspersed by dynamic mid FRET regions throughout the length of the trace
aligned with the light presence of C2 in the corresponding EMSA gel. As shown in
previous figures and in contrast with pdU40, pdU50 exhibits a broad mid FRET peak
with fully dynamic time traces. More interestingly, pdU70 bound to RNA displays
a broader histogram peak spanning the low/mid FRET regions. Time traces also
show a split between mid FRET dynamics ranging between 0.4-0.7 (56.7 ± 5.8%) and
low FRET dynamics ranging between 0.2-0.5 (43.3 ± 5.8%). We interpreted the low
FRET dynamic fluctuation as RNA interacting with complex 3 (C3) and the mid
Figure 2-8. (A) Native gel showing Cy3-labeled polyU (U10–U70) and partially duplexed
pdU10–pdU70. (B) EMSA gels for pdU10–pdU70 at increasing concentrations of FUS
(0–500nM). Demarcations for unbound RNA (black arrow), C1, C2, and C3 are shown.
(C) Representative FRET traces at varying RNA lengths, taken with 500nM FUS and
FRET histograms for varying RNA lengths in the absence (light gray) and presence (dark
blue) of 500 nM FUS (right).
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FRET dynamic as C2-RNA interaction. Compared to the dimer C2, trimer C3 is
larger, therefore, separating the ends of the RNA further from one another leading to
lower FRET values.
Together, the smFRET and EMSA results reveal that short lengths of RNA (up to
U30) only allow a monomer of FUS to bind stably, producing a steady high FRET
signal, whereas pdU40 and pdU50 accommodate two FUS molecules to bind, inducing
a dynamic conformational change on the RNA. For pdU70, up to three FUS units can
bind, giving rise to the midand low-range FRET fluctuations, likely representing the
C2 and C3 states, respectively. Here we establish that the length of RNA is important
for regulating FUS valency and, thus, driving the multivalent interactions between
FUS and RNA.
FUS-RNA: a well-defined two step binding
FUS binds to RNA strongly and in a length-dependent manner, but the initial
interaction between the two is not well understood. To better understand initial
FUS-RNA binding, we conducted a real-time flow experiment in which the FRET
changes of pdU50 were monitored while WT FUS was added. Figure 2-9 (left panels)
shows example traces for varying concentrations of WT FUS from 10-500nM. To
represent all the traces in each condition, we created heatmaps (Fig 2-9, right panels)
by overlaying 100-200 traces all synchronized by the start of the trace. Then, at
each frame (0.1ms per frame) FRET efficiency values were normalize and color-coded
using the scale shown from 0-0.25. At low concentrations, which are mainly C1, WT
FUS binds to the RNA with an intermediate mid FRET step before stabilizing at
high FRET. The intermediate steps observed in the heatmaps is long and eventually
replaced by the high FRET population creating a tail. Transitioning from mid-to-
high FRET at this concentration occurs unsynchronized at different times giving rise
to this phenomenon. This trend continues at higher concentrations with a shorter
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Figure 2-9. Real-time flow traces displaying initial FUS-RNA interactions at 10, 50, and
500nM (left) heatmaps generated by overlaying >100 traces (right) representative traces
at each concentration.
and shorter intermediate step. Moreover, at 500nM the molecules exhibit partially
dynamic interactions showcasing the beginning of the fully dynamic RNA interactions
observed in Figure 2-2B. It is noteworthy that no matter the WT concentrations,
the molecule goes to high FRET and from there the dynamic interactions. These
observations suggests that this stable high FRET state achieved through the mid
FRET intermediate step, which is the proper and core C1 state from which the
following interactions commence.
The intermediate step appears to be characteristic of FUS binding to RNA and it
may be caused by conformational changes in the RNA induced by FUS binding. To
address the nature of FUS binding to RNAin more detail, we performed the same
real-time flow experiment but with singly Cy3-labeled pdU50 at the 5′ end of the
ssRNA, "tail" construct, and at the 5′ end of the 18-mer, "jxn" construct as shown in
Figure 2-10. When FUS binds next to the Cy3 dye, the fluorescence intensity increases
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Figure 2-10. Representative PIFE traces for (A) tail and (B) jxn constructs. Red arrows
depict the increase in Cy3 intensity from protein binding. (C) Histograms of the binding
time calculated from the flow for tail, jxn, and FRET at 2.5nM WT FUS. The bar graph
is the fitted decay constant (τ) and the STD of the fit.
due to protein induced fluorescent enhancement (PIFE) property of Cy-dyes which is
distant sensitive [109].
Figure 2-10A and B show example traces for the tail and jxn pdU50 constructs,
respectively. At 2.5nM, which is highly monomeric, FUS binds close to the tail end at
varying times giving rise to sudden fluorescent intensity surges. This binding pattern
is also observed in the jxn construct but is delayed compared to the tail construct. To
analyze the times in more detail, we calculated the time it takes for FUS to bind each
construct simply by measuring the time between the flow and the intensity increase
denoted with red arrows. Next we plotted a histogram of the collected times and
fitted them with a single exponential decay and extracted the decay constant, τ (Fig
2-10C). Interestingly, the data suggest that FUS binds to the tail end first and then
shifts closer to the junction, with binding times of τtail=6.2±0.4s vs τjxn=11.9±1.9s,
respectively. By comparison, FUS transitions to high FRET in 14.4±1.4s.
In summary, when FUS encounters a partially duplexed RNA, it initially binds to the
available ssRNA causing a conformational change in the RNA leading to a mid FRET
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state. Next, it will fold the RNA tightly (wrap the RNA) and transition from mid to
high FRET. The difference between the high FRET state and the junction binding is
negligible, implying that these steps are concomitant.
WT FUS forms small and fluid droplets with RNA
We next were interested in characterizing WT FUS droplet formation and in presence
of RNA and their biophysical properties. To do so, we used 1µM unlabeled FUS
mixed with 1µM unlabeled U40 RNA doped with 10nM Cy3-labeled U40 (Fig 2-11).
To induce phase separation, the MBP tag was cleaved off using a TEV protease
recognition site between the MBP tag and FUS (Table 4.2). In the absence of TEV
protease, FUS does not form droplets (data not shown). The MBP tag and the
protease alone or in the presence of RNA did not phase separate (data not shown).
Figure 2-11A shows the formation of droplets over time after the cleavage reaction
has started. It usually takes over an hour for the droplets to form and settle at the
bottom of the imaging well. Figure 2-11B shows the area of droplets at each given
time measured using intensity thresholing. As shown in the image, the droplet area
increases until 3 hours and then it plateaus.
To measure the fluidity of the droplets, we performed fluorescent recovery after
photobleaching (FRAP), in which the whole droplet was bleached with high-energy
laser and fluorescent intensity recovery over time was measured (method section 4).
Thus, the recovery rate reflected the degree of RNA exchange in and out of the droplet
and its mobility within the droplet, both of which can indirectly indicate the fluidity
of the droplets. The recovery included corrections for background subtraction and
normalization using overall photobleaching. As observed in Figure 2-11C, WT FUS
fluorescence recovery was nearly 100% in early hours and ages slowly as the time
passes. This suggests that WT droplets are highly fluidic and can exchange with the
surrounding environment very rapidly. We next tested what concentration does WT
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Figure 2-11. (A) Formation of 1µM WT FUS droplets with 1µM U40 RNA at different
time points after TEV cleavage. (B) Area quantification for droplets over time. (C) FRAP
curves showing normalized fluorescent intensity of WT droplets over time. (D) WT FUS
droplet formation at various concentrations at 1µM WT and 1µM U40 RNA. (E) Total
area covered by droplets in D versus FUS concentration to calculate the Csat. All data are
shown as mean±SEM. Scale for images in A and D is 20µm.
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start forming droplet which is better known as its Csat [71]. Figure 2-11D and 2-11E
depicts the concentration dependency of droplet formation. According to Wang et al.
[71], to calculate the Csat, the total area covered by droplets is plotted against the
concentration of the protein and the linear region is then fitted. Csat is the intersection
of the fitted linear line and the x-axis which in this case is equal to 0.72 ± 0.14µM.
RNA-protein dynamics correlate with droplet properties
So far, we have tested the protein interaction with the RNA at two different scales,
single molecule and droplets. But is it possible to link together properties we observe
at each level? For instance, could we compare the fluidity and viscosity of two
protein-RNA droplets just by looking at its RNA interaction at single molecule? To
test this, we performed single molecule FRET using the same RNA construct in
Figure 2-2B, but WT protein was introduced with TEV protease to induce the phase
separation mimicking droplet conditions. Figure 2-12A displays the representative time
traces for multipme time points after TEV cleavage. As it is evident from the figure,
the frequency of dynamic bursts occurring decreases as the protein ages. Further
quantifying the time between two consecutive FRET fluctuation (δt) in Figure 2-12B
confirms our observation.
We performed droplet assay similar experiments described earlier and extracted
apparent diffusion constants by fitting the normalized FRAP curves at 0.5, 2.5, and
3.5h after starting the TEV reaction (Fig 2-12C). Excitingly, the apparent diffusion
constant from the droplets linearly correlates with the rate of FRET fluctuations
measured in single molecule experiments (Fig 2-12D). Essentially, the more frequent
the dynamic RNA interactions at the single molecule level are, the more fluid-like the
formed droplets also are. This conclusion is schematically illustrated in Figure 2-12E.
Another example of this correlation between droplet fluidity and RNA fluctuations
involves Whi3 droplets formed in presence of CLN3 and BNI1 RNAs [74, 110]. Whi3 is
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Figure 2-12. (A) Representative smFRET traces for TEV cleaved WT FUS with pdU50
from 0.5-3.5 hours after cleavage (B) Histograms showing the time between two consecutive
FRET event (δt). The data is fitted by a single exponential decay and the rate constant
(τ) is reported with STD of the fit as the error. (C) FRAP curves from bleaching WT
droplets fitted with A(1 − e−tτ ). (D) correlation plot between apparent diffusion constant
from FRAP and FRET fluctuation rate. (E) Illustration showing the relationship between
single molecule dynamics and fluidity.
an RNA binding protein in Saccharomyces cerevisiae with long stretches of Glutamine
which functions in morphogenesis, stress response, and memory of mating [111]. Its
homolog in Ashbya gossypii has an RNA recognition motif (RRM) and can go through
a liquid-liquid phase separate driven by specific RNAs that encodes for cell cycle
regulators (e.g., the cyclin CLN3) or actin regulators (e.g., the formin BNI1) [74]. In
vivo, droplets formed by Whi3 in the presence of CLN3 localize to the perinuclear
regions, whereas, BNI1 droplets localize at the polarized sites of growth. In addition
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to localization, the amount of incorporated Whi3 in either droplets giving rise to
different properties [74].
To test Whi3 binding to RNA, we used smFRET to measure the conformational
dynamics of CLN3 and BNI1 mRNAs with and without Whi3 (2-13). The RNA
constructs are similarly prepared to pdU50 but the polyU ssRNA is swapped with a
portion of CLN3 and BNI1 mRNA, which contains the Whi3 binding motif. In the
absence of protein, CLN3 RNA showed high FRET values indicative of a compacted
state, whereas BNI1 RNA showed lower FRET values, indicating a less compact state
(Fig 2-13A). Upon addition of Whi3, FRET peaks for CLN3 shifted to lower value
extending the RNA after binding (Fig 2-13A). However, the FRET histogram peak
for BNI1 didn’t change much in position but exhibited significant broadening. Figure
2-13B shows representative traces for CLN3 and BNI1 in the presence of 5µM Whi3.
The traces suggest that BNI1-Whi3 interaction is consist of faster dynamic interactions
as oppose to CLN3. To compare the dynamics, we measured the time between two
consecutive FRET fluctuations. Figure 2-13c and D show the result for the dwell-time
analysis both RNA constructs with 500nM and 5µM Whi3. It is evident from the
graphs that CLN3 has slower dynamic RNA interactions compared to BNI1. We know
that for WT FUS, the faster the dynamic RNA interaction, the less viscous and more
fluid the droplet. Does this relation hold for Whi3?
Zhang et al. [74] reported in their work that CLN3 and BNI1 droplets have very
distinct properties. In vitro, BNI1 droplets are almost twice as less viscous than
CLN3 droplet and these droplets are immiscible both in vivo and in vitro. Our single
molecule data combined with the existing literature suggests that these differential
dynamics help maintain droplet identities established by RNA-RNA interactions.
Once RNA-RNA interactions are formed, Whi3 binding may reduce the ability of the
RNA to resample many alternate RNA structures to maintain the droplet identity.
In addition, the slower fluctuations of CLN3 bound to Whi3 may be one source of
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Figure 2-13. (A) FRET histograms for BNI1 and CLN3 RNA before and after of Whi3
addition. (B) Representative traces showing donor (green) and Acceptor (red) intensities
alongside FRET traces (blue) obtained from smFRET experiments of CLN3 and BNI1 in
the presence of 5µM Whi3. Dwell-time analysis reveals slower FRET fluctuations for (C)
BNI1 and (D) CLN3. The decay constants are calculated for a single exponential decay
reported with STD errors.
exclusion from the more rapidly fluctuating BNI1-Whi3 complexes in those droplets
such that RNA tunes the properties of these droplets.
WT FUS as a baseline: Characteristics
So far, we were able to investigate different aspects of the flowchart shown in Figure 2-1
and update the chart to Figure 2-14. We showed that FUS in contact with pdU50 RNA
forms a monomer (C1) and then a dimer (C2) during its path to droplet formation.
Here we summarize some of these features:
• Complex 1 (C1)
– Monomer in nature
– First shifted band from the RNA on EMSA
– High FRET static RNA interaction in smFRET
– Dominant at lower concentrations of FUS
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Figure 2-14. Flowchart showing FUS-RNA droplet formation steps from single molecules
to phase separated bodies with the characteristics of each step
– FUS binds to RNA in two steps
• Complex 2 (C2)
– Dimer in nature
– Second shifted band from the RNA on EMSA
– Mid FRET dynamic RNA interaction in smFRET
– Dominant at higher concentration
• Phase separated droplets
– Small droplets in size
– Highly fluidic droplets with high mobilize fraction
Establishing these characteristic features qualitatively and quantitatively lays the
foundation for answering our pressing question mentioned at the beginning of the
chapter; "How do different portions of WT FUS contribute to its overall RNA interac-
tion?" and "How do mutations differ in RNA interactions compared to the WT?". We
will address each question in the upcoming sections and chapters.
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Dissecting WT FUS RNA interaction by regions
So far, we thoroughly characterized WT FUS and how it interacts with RNA. We
established a road-map to study the FUS-RNA interaction (Fig 2-14) in which the
WT behavior is the reference. We observed that the WT bind to the RNA to form
the monomer complex 1 (C1) in a well-defined two-step fashion. This state transitions
to a stable dimer complex 2 (C2) at higher concentrations giving rise to the dynamic
RNA interactions. Formation of C1 and C2 as described will lead to smaller and
highly fluid droplets. In this section, we investigate different domains of WT FUS
and their roles in interaction with RNA.
FUS is a highly disordered protein that drives LLPS by its low complexity domain
(LCD) and RNA binding domain (RBD) [25, 30, 43, 65–67]. The length of the protein
can be divided into multiple domains as shown in Figure 1-2: the N-terminal LCD
which is also known as the prion-like domain (PrLD) [54]; three RGG domains which
are enriched in arginine and glycine; an RNA recognition motif (RRM); a Zinc finger
domain (ZnF); and a nuclear localization signal (NLS) at the C-terminus. For the
purposes of this thesis, FUS can be bisected into two halves: LCD and the RNA
binding dom ain (RBD). A more careful examination of the domain map shows that
FUS is highly asymmetric. The N-terminus of the protein (LCD region) is almost
exclusively disordered whereas the C-terminus consist of highly ordered regions flanked
by disordered patches. In terms of composition, LCD and RBD are highly asymmetric
as well. LCD mainly contains a small subset of amino acids such as glutamine (Q),
serine (S), glycine (G) and enriched in aromatic residues like tyrosine (Y) [68–70]. On
the contrary, RBD is consist of highly order regions separated by disordered patches
(RGG domains) which is also enriched in charged residues like arginine (R) and glycine
(G)[71]. We want to further understand this asymmetry and who would that affect
the RNA interaction of WT FUS.
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Figure 2-15. Disorder map of WT FUS
RBD is responsible for the two-step RNA binding in WT
We purified LCD and RBD individually and performed flow experiments using the
pdU50 FRET RNA construct as described for WT FUS (Fig 2-16). Remarkably, the
two domains of WT interact with immobilized pdU50 RNA differently at varying
concentrations. LCD exhibits a very clear one step binding at low concentrations
(10nM) as seen in Figure 2-16A. The divergence in the heatmap comes from the
wide distribution of RNA binding times of LCD. As the concentration increases to
50nM, the binding stays single-stepped but binding times decrease and cluster toward
the beginning of the heatmap. At high concentrations (500nM), the binding is still
single-step but highly dynamic interactions are observed immediately after completing
the binding and transitioning to high FRET.
In contrast with LCD, Figure 2-16B shows that RBD binds to the RNA in two-steps
very similar to the WT (Fig 2-9), and this is seen in the heatmap and the representative
traces. At mid and high concentrations, 50 and 500nM, the two-step binding patterns
is still observed but the duration of the intermediate step shortens as the concentration
increases. However, there is a clear difference between RBD and WT FUS interacting
RNA where WT shows a very well-defined intermediate step and transition to high
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Figure 2-16. Representative smFRET flow traces (right column) and heatmaps (left
column) using immobilized pdU50 RNA on the surface at varying concentrations of (A)
LCD and (B) RBD from 10-500nM.
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FRET (Fig 2-9) compared to RBD. Moreover, the FRET value of the intermediate
state is slightly higher for RBD than it is for WT. The smaller gap between the
intermediate and final high FRET bound state causes the transitions the two step
binding of RBD not to be as well-defined as the WT (Fig 2-16B).
These data combined suggest that the RBD domain of the WT is mainly responsible
for properly binding to the RNA. But why would the LCD bind to the RNA giving
rise to the tight RNA folded high FRET state? Possibly, the LCD and it’s many
aromatic residues interact with the RNA in more non-specific way. This incorrect
binding mode gives rise the one-step transition to high FRET forming an improper
C1. In contrast to LCD, RBD’s RNA binding mode resembles the WT and forms
proper C1. But, can LCD and RBD together in trans recapitulate the WT behavior?
Figure 2-17. Representative smFRET flow traces (right column) and heatmaps (left
column) for equimolar mixture of LCD and RBD at varying concentrations from 10-500nM.
It is reported that mixing LCD and RBD can indeed mimic the WT phenotype
[71]. We tested this possibility by flowing equimolar LCD and RBD which are
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independently purified and monitor its FRET changes over time reported in Figure
2-17. At low concentrations, we obtained miwed patterns of single molecule traces that
resemble RBD (two-step) and LCD (one-step) binding. This could be due to the low
concentration of the protein and the competition between LCD and RBD monomers
in binding to the RNA. As the concentration increases (50 and 500nM), the molecules
resemble WT-RNA interactions, likely due to RBD dominating the RNA binding
since RBD resembles the WT characteristics. Yet, the initial RNA interaction fails to
recapitulate the very well-defined intermediate step observed in WT (Fig 2-9). This
suggests that simply combining the two halves of FUS is not sufficient to recapitulate
normal RNA binding.
RBD binds to RNA after multiple attempts; LCD binds im-
mediately
To understand the differences in RNA binding between LCD and RBD, we altered
the labeling scheme of our experiment. We kept Cy3 dye at the tail end of pdU50
similar to Figure 2-10A and instead placed the Cy5 dye on FUS using NHS-ester
chemistry. We then performed flow experiments using Cy5 labeled WT, LCD, and
RBD FUS (Fig 2-18). We observed that WT FUS exhibits two different binding
patterns as shown in Figure 2-18A: 1) Attempted binding and 2) immediate binding
as shown in Figure 2-18A. Attempted binding refers to transient increases in the Cy5
intensity and FRET levels prior to a stable high FRET binding. In some cases, these
attempts do not lead to binding in the observable time widow or before either dye
photobleaches. Another observed pattern is immediate binding without any attempts.
It is noteworthy that this one-step binding is inherently different than the one step
binding observed earlier using FRET pdu50 RNA Fig 2-9 due to the altered labeling
scheme. More than 80% of molecules upon addition of 2.5 and 10nM labeled protein
exhibit attempted binding (Fig 2-18D). We hypothesized that the attempts observed
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in attempted binding category could be indicative of FUS finding its proper RNA
binding configuration through RBD and finally binding stably to the RNA.
Figure 2-18. Representative flow traces for (A) WT, (B) LCD, and (C) RBD FUS. The
protein is labeled with Cy5 and the pdU50 RNA is labeled with Cy3 at the tail position.
Black dashed line shows the moment of flow . (D) Quantification showing the percent
molecules exhibiting immediate binding and attempted binding for each protein construct
at 2.5 and 10nM.
To test this hypothesis, we labeled LCD and RBD with Cy5 and tested them separately
using a similar setup describe above. LCD predominantly immediately binds to the
RNA without any attempts before binding (Fig 2-18C). On the contrary, RBD
undergoes many binding attempts before stably interacting with RNA. The results
in in Figure 2-18D show a clear deviation between two observed binding patterns
mention earlier (attempted binding and immediate binding). LCD exhibits more than
80% immediate binding and RBD shows more than 70% attempted binding patterns.
Considering this result alongside the WT data, the RBD half of the protein is likely
responsible for the repetitive binding attempts observed with WT FUS. We showed
earlier (Fig 2-18) that RBD forms proper C1 and resembles the two-step RNA binding.
Additionally, our observations in Figure 2-18 reinforce our hypothesis that RBD is
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mainly responsible for proper RNA binding and C1 formation by potentially scanning
possible binding configurations.
Functional RRM is crucial for proper WT-RNA interaction
and C1 formation
So far, we established that the RBD domain is mainly responsible for proper binding
of WT to the RNA. To further understand which regions of the RBD are necessary
for proper RNA binding, we made two different variants of FUS: 1) RBD∆RGG1,
a truncation of the RBD in which the RGG1 domain that links the LCD to RBD
is deleted; and 2) 3FL, which is a non ALS-linked FUS variant that has three
phenylalanine (F) amino acids from the RRM region (F305L, F341L, and F359L)
mutated to leucine (L) impairing its RNA recognition and interaction [104, 112]. If
the RNA binding capability of FUS is critical for its proper interaction to RNA, we
hypothesized that the RBD∆RGG1 should behave similar to RBD whereas 3FL should
behave similar to LCD.
smFRET flow experiments performed with both of these constructs confirmed our
hypothesis. RBD∆RGG1 exhibits lower RNA binding affinity compared to the
RBD (Fig 2-19A) but as the concentration increases the signature two-step binding is
observed. This suggests that the RGG1 domain plays an important role in maintaining
high RNA affinity. This is consistent with reports that RGG1 assists the RRM domain
and mutations in this domain decreases RNA affinity [82]. On the other hand, 3FL
mimics LCD RNA binding at all tested concentrations (Fig 2-19B). At 10nM, the
heatmap binding patterns resemble LCD. Although, the nature of the intermediate
state becomes a mixture of two- and one-step binding at higher concentrations, the
majority of molecules (more than 80%) exhibit an LCD-like one-step binding.
Altogether, these results demonstrate that the WT requires its RNA recognition and
canonical RNA binding capability to form proper C1 via a two-step initial RNA
43
Figure 2-19. Representative smFRET flow traces (right column) and heatmaps (left
column) using immobilized pdU50 RNA on the surface at varying concentrations of (A)
RBD∆RGG1 and (B) 3FL from 10-500nM.
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interaction.
Complex 2 (C2) characterization
In the previous sections, we explored the role of different fractions of FUS according
to our framework presented in Figure 2-14. We showed that a well-defined two-step
RNA binding pattern is a characteristic feature of C1 for WT and RBD FUS. We
next wanted to understand how the proper formation of C1 impacts the maturation of
higher order complexes; therefore, we explored the characteristics of the C2 complex
in more detail as shown in Figure 2-20. To do so, we performed smFRET using
our typical pdU50 immobilized on the surface and introduced 500nM of WT, LCD,
RBD, LCD+RBD, and 3FL FUS individually. The sample FRET traces are displayed
in Figure 2-20A. WT FUS exhibits highly dynamic interactions with the RNA as
expected. LCD’s RNA interaction is mainly dynamic but the nature and the range of
dynamic FRET fluctuations are different. The RBD and LCD+RBD conditions also
have altered mid-FRET dynamics and dwell times.
To compare the different dynamic behaviors for each construct, we calculated and
visualized the fraction of time spent by each molecule in its non-static state (mainly
mid FRET) using violin plots shown in Figure 2-20C. We also histogramed those
collected portions from over 100 traces and plotted the heatmap of FRET fluctuation
ranges for each construct (Fig 2-20B). The WT violin plot (Fig 2-20C) shows an
accumulation in the values closer to 100% meaning that the traces are mainly in the
non-high FRET state with a wide range of FRET fluctuations from ∼0.2-0.8 with
the highest density around 0.5 (Fig 2-20B). Interestingly, LCD’s violin plot displays a
concentration of higher values, however, the range of fluctuation way more constricted
compared to the WT varying from 0.4-0.6 with the center around 0.5. For other
constructs, RBD, LCD+RBD, and 3FL, the majority of the traces are high FRET
static expressed by the violin plot and the values accumulating at the bottom of the
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Figure 2-20. (A) Representative traces of 500nM WT, LCD, RBD, LCD+RBD, and 3FL
using pdU50 RNA (B) Histograms and heatmaps of FRET dynamic range of traces (only
the not static state was collected) for all mentioned FUS truncations corresponding to
traces in A. (C) Violin plot showing fraction of time each molecule spends in the non-high
FRET state.
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plot. Looking at the heatmaps (Fig 2-20B) reveals that the fluctuation range for these
constructs is closer to the WT but the densest region closer to 0.4 and a bimodal
distribution.
LCD does not form droplets with RNA at physiological con-
centrations
Figure 2-21. (A) Droplet formation of LCD and RBD at 1, 2.5, 5µM protein in presence
of equimolar unlabeled U40 RNA doped with 10nM Cy3-U40. The images are taken at
4hrs after TEV cleavage reaction. Scale bar is 20µm. (B) FRAP diagrams for WT and
RBD after 3hrs.
All the data up to this point elucidates to starkly different RNA interaction modes
for the LCD and RBD regions. These defects may propagate to larger scales and
effect either droplet formation or droplet properties. To assess this, we first tested
the droplet formation of each domain in the presence of U40 as shown in Figure
2-21A. Interestingly, we observed that the LCD does not form droplets even at 5µM
whereas the RBD forms WT-like droplets even at lower concentrations. Although RBD
droplets are morphologically similar to WT droplets, they have different biophysical
properties such as fluidity. FRAP measurements reveal that at varying concentrations,
RBD is consistently less fluidic than the WT (Fig 2-21B). The improper C1 formation
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Figure 2-22. (A) Droplet formation over time for different FUS constructs at 1µM protein
concentration with 1µM U40 RNA. Scale bar is 20µm. Quantification for (B) total area
covered by droplets and (C) droplet area over time.
may inhibit droplet formation for LCD, but the lack of LCD may be required for
normal droplet maturation.
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Further perturbations in the RBD domain may alter droplet formation as well. To
investigate this further, we performed our droplet formation assay at 1µM FUS and
1µM U40 RNA for a variety of FUS constructs over time shown in Figure 2-22A. As
expected, LCD does not form any droplets even after 6h of incubation, but, RBD forms
droplets similar to the WT. Interestingly, the LCD+RBD condition forms droplets
similar in shape and fluidity to the RBD (data not shown). This suggests that at
higher concentration, RBD tunes the droplet behavior in terms of RNA interaction and
droplet formation. Moreover, 3FL fails to form droplets properly which is consistent
with our hypothesis. Droplet quantification in Figure 2-22B and C reveal that WT
and RBD droplets are about the same size. However, 3FL forms droplets with similar
area to those few formed LCD droplets but the total covered area is at least two fold
lower than WT or RBD FUS.
Discussion and conclusion
WT FUS & RNA: A molecular reference for being normal
In the first half of this chapter, we described efforts to develop a quantitative and a
qualitative framework to study disordered RNA binding proteins, especially FUS, and
investigated how these proteins form phases from in a systematic manner. We focused
on understanding how WT FUS interacts with RNA and forms condensates from a
molecular perspective. We showed that the WT FUS in contact with pdU50 RNA
initially forms a monomer complex (C1) and then a dimer complex (C2) on its path to
droplet formation. C1 forms a stable complex with the RNA exhibiting a static high
FRET interaction with the RNA whereas C2 that emerges at higher concentrations
interacts in a dynamic manner. These interactions are also dependent on the length
of the RNA. In most of our experiments, we use a 50nt polyU RNA with Cy3-Cy5
FRET pairs but upon varying the length of the RNA we observe that short lengths of
RNA (up to U30) only allow a monomer of FUS to bind stably, producing a steady
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high FRET signal, whereas pdU40 and pdU50 accommodate two FUS molecules to
bind, inducing a dynamic conformational change on the RNA. At a higher length,
pdU70, up to three FUS units can bind, giving rise to the mid and low-range FRET
fluctuations, likely representing the C2 and C3 states, respectively. This is consistent
with the literature that has shown the valency of the RNA which can control the
protein binding and phase separation [75].
Single molecule methods enabled us to study the FUS-RNA binding modes and
interactions. When WT FUS interacts with a partially duplex RNA, it initially binds
to the available ssRNA causing a conformational change in the RNA giving rise
to the mid-FRET state. Next, it will fold the RNA tightly (wrap the RNA) and
transition from mid to high-FRET. This proper RNA binding leads to a dynamic
C2 formation which then results in phase separated bodies that smaller in size and
more fluid. This has been known to be a normal FUS condensate’s characteristic
both in vivo and in vitro. It is noteworthy that WT FUS, which binds ssRNA with
nanomolar affinity (based on our EMSA analysis), is present in cells at a concentration
of sim3µM[85]. The emerging view is that the long cellular mRNA can be targeted by
multimers of FUS inducing highly dynamic interactions with the cellular RNA. In the
cytoplasm where the RNA-to-protein ratio is low, such dynamic, multivalent protein-
RNA interactions can also lead to coalescence into RNP condensates. We envision
that proper RNP condensation entails two sequential steps: the initial protein-RNA
interaction and the subsequent RNP-RNP interaction mediated by protein-protein
contact. Our results obtained for the WT FUS reflect that multimer C2-induced
dynamic FUS-RNA interaction is the proper protein-RNA format that supports the
subsequent FUS-RNA:FUS-RNA interaction that leads to LLPS.
Here we summarized the WT FUS characteristic features:
• Complex 1 (C1)
– Monomer in nature
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– First shifted band from the RNA on EMSA
– High-FRET static RNA interaction in smFRET
– Dominant at lower concentration
– Binds to RNA in two steps
• Complex 2 (C2)
– Dimer in nature
– Second shifted band from the RNA on EMSA
– Mid-FRET dynamic RNA interaction in smFRET
– Dominant at higher concentration
• Phase separated droplets
– Small droplets in size
– Highly fluidic droplets with high mobilize fraction
RBD-LCD synergy in WT FUS gives rise to its RNA interac-
tion properties
In the second half of this chapter, we investigated the role of different domains of
WT FUS in RNA interaction and condensate formation. We divided the protein in
two segments, low complexity domain (LCD) and RNA binding domain (RBD) and
performed various single molecule and droplet assays using these protein constructs.
At a larger scale, our results show that LCD in the presence of RNA does not form
droplets whereas RBD forms droplets resembling the WT FUS (Fig 2). Based on
our observations from WT FUS there is correlation between properties of formed
FUS-RNA complexes and the droplet formation (Fig 2-12). Therefore, we hypothesized
that this stark difference comes from different RNA interaction patterns for LCD and
RBD. A closer look at FUS’s sequence reveals the strong asymmetry with LCD being
highly disordered and enrich in tyrosine, whereas, RBD is more ordered harboring the
RRM domain and enriched in arginine.
Further experiments revealed that LCD binds to RNA in one step as oppose to the
typical two-step binding observed in WT FUS. By contrast, RBD bind to the RNA
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with two-steps similar to the WT. These different modes of binding for LCD and
RBD is observed at all concentration, especially at lower concentrations that FUS is
mainly monomeric (C1). We think that LCD with its single-step binding is unable to
form proper C1, in contrast with the proper C1 formation of RBD. We next showed
that the RNA binding ability of FUS is critical for its two-step binding to RNA and
proper C1 formation (Fig 2-19). We used a FUS variant, 3FL FUS, that has mutations
in the RRM domain and is known to have impaired RNA binding. 3FL binds to
RNA similar to LCD going from low to high FRET in a single step and its droplet
formation propensity is drastically reduced. This further strengthens our finding that
the two-step RNA binding pattern of WT is the proper C1 formation.
Given the importance of proper C1 formation, we hypothesized that the differing RNA
interaction modes for LCD and RBD is likely to seed altered C2 formation. Detailed
analysis of single molecule traces in the presence of 500nM WT, LCD, and RBD FUS
showed that the dynamic fluctuation ranges are different between these constructs.
LCD’s improper C1 formation leads to a locked C2 state where the FRET fluctuations
are restricted. On the other hand, RBD which forms a C1 state closer to the WT,
behaves similar to the WT at the C2 state as well. Altogether, we think there is a
strong correlation between droplet formation and its properties and the proper C1




FUS mutants: formation and
reversal of aberrant phase
separation
In the previous chapter, we investigated in molecular detail how WT FUS interacts
with polyU RNA and forms phase separated droplets in vitro. We also investigated
how each major domain of FUS contributes to the proper RNA interaction and
drives proper droplet formation. In this chapter, we focus on understanding how
ALS-linked mutations in FUS differ from the WT in terms of RNA interaction and
phase separation and how this may be liked to disease. We found R-mutants and
G-mutants had distinct phenotypes that may contribute to the disease state through
different mechanisms
Assembly of aberrant FUS-RNA complexes in ALS-
linked FUS mutants
Mutations in FUS and other SG RBPs are causative agents of neurodegenerative
diseases like ALS and frontal temporal d ementia (FTD) [86, 88, 92–94, 100, 101,
113–116]. ALS/FTD mutants of FUS incorporate into normal fluid SGs and induce
conversion to irreversible pathological aggregates in the course of disease progression
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Figure 3-1. ALS-linked mutations distribution through FUS protein
[7]. There are more than 70 FUS mutations found in patients with ALS which are
mostly clustered in the disordered regions especially the NLS region shown in Figure
3-1. The most frequently observed patient occurring mutations substitute Arginine
(R) and Glycine (G) amino acids. These residues have been described as sticker and
spacer residues, respectively, contributing the biophysical properties of phase separated
granules [71]. The R and G mutations are highlighted in Figure 3-1 in red and green,
respectively.
We sought to determine if these mutations are aberrant at the level of RNA-interaction
and phase separation by studying several ALS-linked mutations using similar methods
described in Chapter ??. TAlthough we analyzed all mutants, we chose R244C to
study in more detail as a representative for sticker mutants.
Unlike WT, the R244C-RNA interaction is static
The R244C mutation is located within FUS disordered domain, adjacent to the RRM,
and it is associated with severe neurological dysfunction in ALS patients [7, 53, 117].
We examined whether R244C interacts differently with RNA compared to WT FUS
using the same smFRET assay described before using pdU50 FRET RNA immobilized
on the surface (Fig 3-2). Unlike WT, R244C binding to RNA at 5nM results is a
split between mid and high-FRET time traces as shown in Figure 3-2A. The FRET
histogram at this concentration also shows two populations at high and mid-FRET. As
the concentration increases, the shape of the histogram does not change significantly.
At concentration ranging from 50-500nM, RNA molecules exhibit mainly static high
FRET traces with infrequent excursions to mid-FRET states (Fig 3-2A). This is in
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Figure 3-2. (A) Representative FRET traces and histograms for R244C taken at varying
protein concentrations (5–500nM). (B) EMSA gel using pdU50 at varying R244C concen-
trations; arrows denote the RNA band (black arrow), C1, the absence of complex 2 (C2),
and aggregation.
stark contrast to the highly dynamic WT FUS interaction with the RNA (Fig 2-2B).
In agreement with smFRET results, EMSA using the pdU50 FRET RNA at varying
R244C concentrations reveals that R244C-RNA directly transitions from a C1 complex
at low concentrations to an aggregation state at high concentrations without forming
the C2 state, which we previously showed was responsible for WT dynamic RNA
interactions (Fig 2-5). Therefore, we think the lack of C2 and the impaired RNA
interaction of R244C is mainly responsible for the observed aberrant RNA interaction.
It is noteworthy that C1 appears at higher concentrations than the WT suggesting
that R244C’s RNA binding affinity is reduced which was confirmed using anisotropy
(data not shown).
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Loss of Arginine drives R244C-RNA aberrant interaction
Is the altered RNA binding of R244C due to the loss of arginine or the gain of cysteine
at that position? In order to test these possibilities, we prepared two non-ALS variants,
R244K and R244A. Lysine is positively charged and only slightly smaller than arginine
(Fig 3-3A, meaning if R244C’s altered RNA interaction arises from only the loss of
a positively charged amino acid (arginine), then R244K should resemble WT FUS,
whereas R244A should mimic R244C. However, if the altered RNA interaction is
caused by the gain of cysteine, then neither R244K nor R244A should resemble R244C
rather be more similar to the WT. Indeed, the smFRET result for R244K showed
increasing levels of dynamic FRET fluctuations as a function of protein concentration
(Fig 3-3B), highly similar to FUS-WT (Fig 2-2B). By contrast, R244A displays mainly
static smFRET traces with infrequent dynamics (Fig 3-3C), similar to R244C (Fig
3A).
The EMSA shows that R244K forms C2 starting from 25nM concentration (Fig
3-3D), concurrent with the emergence of smFRET dynamics, again similar to WT
FUS (Fig 2-2B). However, R244A fails to form C2 even at high concentrations and
aggregates (Fig 3-3E), resembling the R244C pattern shown in Figure 3-2B. Unlike
WT, we observed a small degree of aggregation for R244K at high concentrations.
This suggests that not only is arginine’s charge is important, but its shape and size
allows formation of C1 and C2 without aggregation.
Taken together, we demonstrate that loss of the positively charged arginine in R244C
and R244A is primarily responsible for the altered interaction with RNA. The R244C
mutant may seed defective complex formation that drives the increased aggregation
seen in the disease. The substitution analysis strongly suggests that arginine is critical
for properly engaging with RNA (C1) and that formation of C1 is necessary for
formation of C2, which exhibits a dynamic interaction in the WT.
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Figure 3-3. (A) Chemical structure of involved amino acids (B,C) Representative FRET
traces and histograms for (B) R244K and (C) R244A taken at varying protein concentrations
(5, 50, and 500nM). (E,F) EMSA gels using pdU50 at varying (E) R244K and (F) R244A
concentrations; arrows denote the RNA band (black arrow), C1, the absence of complex 2
(C2), and aggregation.
Defective RNA binding of R244C is evident at initial stages
of interaction
The smFRET traces of R244C at low concentration in Figure 3-2A exhibits a mixture
of high-FRET and mid-FRET static traces which is different that the WT FUS (Fig
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Figure 3-4. Real-time flow traces displaying initial R244C-RNA interactions at 5, 50, and
500nM (left) heatmaps generated by overlaying >100 traces (right) representative traces
at each concentration.
2-2). This data combined with the EMSA from Figure 3-2B led us to hypothesize
that the initial binding of a monomer may be altered in R244C, which would lead to
improper C2 engagement and higher aggregation propensity. To asset this possibility,
we performed a real-time flow experiment in which smFRET videos were taken while
adding R244C to the immobilized pdU50 RNA. These real-time videos allows us to
capture the initial moment when the protein contacts the RNA [118].
Figure 3-4 (right side) shows representative traces observed at varying concentrations
of R244C. The heatmap generated by overlaying more than 100 traces in Figure 3-4
(left side) displays how R244C interacts with the RNA on average. Unlike WT (Fig
2-9) well-defined two-step binding, R244C binding is significantly slower and exhibits
a poorly defined low FRET state that does not transition to a high FRET state for
more than 50s. This delay and improper RNA interaction at lower concentrations
(C1 dominant regime) results in a heatmap with highly scattered patterns. As the
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concentration increases, the intermediate step is observed but is never well-defined as
it is for the WT FUS.
To further investigate the binding mechanism of R244C we utilized a different single-
molecule technique PIFE [109, 119]. We used two versions of the pdU50 construct,
each with Cy3 dye at either end of the U50 so that FUS binding can be detected
on either end independently [120]. Again, unlike WT FUS (Fig 2-10), addition of
R244C exhibited very delayed, less distinct, and non-uniform signal increase (Fig
3-5A and B) consistent with the irregular pattern observed in FRET measurement
(Fig 3-4). We quantified the binding times for both the tail and junction construct
in presence of 5nM R244C which is shown in Figure 3-5C. Although both WT and
R244C show similar patterns in term of binding orders (tail binding first), R244C
binds with significant time delay. This time delay is also consistent with the delayed
high-FRET binding (Fig 3-5C).
Figure 3-5. Representative PIFE traces for (A) tail and (B) jxn constructs at 5nM R244C.
Red arrows depict the increase in Cy3 intensity upon protein binding. (C) Histograms
of the binding time calculated from the flow for tail, jxn, and FRET at 5nM R244C and
2.5nM WT FUS for comparison. The bar graph is the fitted decay constant (τ) and the
STD of the fit.
In summary, R244C exhibits irregular binding to RNA so that it forms a defective C1
state that is incompatible with C2 formation, that we propose leads to aggregation
at high concentrations. The aberrant RNA binding pattern was also observed at
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higher protein concentrations. The C1 band present in the EMSA gel across R244C
concentrations signifies the persistent nature of the defective monomer-bound state.
Together, our results provide strong evidence that proper formation of the C1 state is
necessary for formation of a dynamic C2.
Arginine and Glycine exhibit different RNA interaction pat-
terns
We next wanted to see whether these altered RNA interactions observed in Section
3 are observed in other ALS-linked mutations. The mutations we selected are as
follows: five Arginine (R) mutations (R216C, R244C, R514G, R521C, and R521G),
five Glycine (G) mutations (G156E, G187S, G225V, G230C, and G399V), two NLS
mutations (R495X and P525L), and two non-ALS control mutations (R244K and
R244A). All the mutations are patient occurring mutations spread throughout LCD,
RGG1, and NLS region of the FUS but the two non-ALS control mutants which are
alternative substitutions for R244. All these mutations are distributed throughout the
LCD, RGG1, and the NLS domain of FUS protein. Our strategy was to probe the
full length of the protein while keeping the sample size relatively short. We tested
all mutations using smFRET shown in Figure 3-6. We observed that almost all of
the R mutations displayed highly static RNA interaction very similar to R244C with
the exception of R514G which showed more dynamic interaction relative to other R
mutations (Fig 3-6C).
To see whether other classes of mutations exhibit similar altered RNA interactions,
we tested two NLS mutations, P525L and R495X, which are associated with an
early-onset, highly aggressive form of ALS. smFRET measurements using immobilized
pdU50 at a high protein concentration (500nM) shows that both NLS mutants interact
with RNA in a dynamic manner, resembling the WT FUS (Fig 3-6A).
We also tested five glycine ALS-linked mutations (G156E, G187S, G225V, G230C, and
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Figure 3-6. (A–C) Representative FRET traces of all mutants taken at 500nM of WT
and NLS mutations (A), five ALS-linked glycine mutants (B), and five ALS-linked arginine
mutants (C). (D) Violin plot showing the population density of the fraction of time spent
in the dynamic (FRET fluctuation) state for individual mutants. The dwell times were
collected from over 200 events.
G399V). Unlike arginine which is a sticker residues, glycine is a spacer residue known
to control biophysical properties of the droplets [71]. The five G mutants displayed a
wide range of interactions with RNA (Fig 3-6B) but overall exhibited substantially
more dynamic FRET fluctuations than R mutants.
To quantify the amount of dynamic fluctuations observed for each mutant, we measured
the fraction of time each molecule (>120 traces per mutant) persists in the dynamic
61
state (from the smFRET traces) at 500nM and plotted the population density in the
form of a violin chart (Fig 3-6D). The dynamic fraction values range from 0 (fully
static) to 100 (fully dynamic). For each mutant, the median of the population and the
mean±SEM was calculated and reported in the table in Figure 3-6D. As expected,
WT FUS is the most dynamic with higher density at values close to 100% (median
score of 0.97) (Fig 3-6D, black). The two NLS mutants (light blue) and the G mutants
(green) display a wide distribution of dynamic fractions arising from traces displaying
both dynamic and static FRET states. With the exception of R514G, all other R
mutants (red) show median scores clustering below 0.2, clearly indicating mostly static
interactions with RNA.
Three distinct classes of patterns are observed in EMSAs on the various mutants as
shown in Figure 3-7. The EMSAs are done with the same pdU50 constructs used in
smFRET at 1nM with varying concentrations of FUS. Class I exhibits C1 formation
at lower concentration which transitions to C2 as the concentration increases with
little to no aggregate at high FUS concentration. WT FUS and two NLS mutations,
P525L and R495X, are in this class. Class II displays a delayed C1 formation at
low concentrations transitioning to C2 with aggregation at higher concentrations.
R244A, R216C, R514G, G156E, G187S, and G225V fall in this category. Class III
is characterized by a persistent C1 but no C2 formation and a direct transition to
high a degree of aggregation. This class contains R244C, R521G, R521C, and G399V
mutants.
These results generally agree with our smFRET data and support the model that
the C2 conformation is responsible for dynamics. At high concentrations, Class I
mutants mostly form C2 in EMSAs and display the highest level of RNA dynamics
in smFRET. Conversely, Class III mutants do not form C2 and readily aggregate
in EMSAs, corresponding to an aberrant static interaction with RNA in smFRET.
Class II falls in between Classes I and III; both C2 and aggregated states generate
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Figure 3-7. EMSA for NLS, arginine and glycine mutations divide in 3 classes based on
RNA-FUS binding patterns at low, mid, and high concentration of FUS.
a mixture of dynamic and static FRET trajectories, respectively. Taken together,
the smFRET and EMSA data orthogonally support that the FUS-RNA interaction
is driven by precise complex formation, with C2 the driving force for the dynamic
FUS-RNA interaction, which is greatly impaired for most arginine mutants.
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Arginine mutants form large droplets; Glycine mutants show
accelerated aging
Next, we were interested in understanding the effect of altered RNA interaction on
droplet formation. Do these defective bindings propagate to the droplet scale? To
address this, we formed FUS droplets of different mutations by cleaving off the MBP
solubility tag using TEV cleavage reactions. All the droplets are formed using 1µM
protein in presence of 1µM U40 RNA.
Figure 3-8A shows droplets for select R and G mutants alongside WT FUS and two
NLS mutants. Consistent with previous studies, this result suggests that ssRNA
promotes phase separation of FUS in the absence of a molecular crowding agent [85].
To visualize the droplets and track the RNA dynamics using FRAP we doped 10nM
Cy3-labeled U40 RNA into the reaction while keeping the concentration of both the
protein and RNA at 1µM. The droplet size was measured using automatic intensity
thresholding over 6hrs of imaging in Figure 3-8B. Based on the data, WT FUS, NLS,
and G mutants form small droplets (areas ∼ 1.5µm2), but the R mutants grow larger
(∼ 3 − 6µm2). Even after 3 hours, a stark difference in droplet size is observed (Fig
3-8C). This is in agreement with the EMSA results; the aggregation prone R mutants
formed into much larger FUS-RNA condensates than FUS variants that showed a
negligible degree of aggregation on EMSA (Fig 3-7).
Next, we performed FRAP photobleaching on entire droplets to compare the fluidity
of different variants. The observed recovery rate reflects the degree of RNA exchange
into and out of the droplet and its mobility within the droplet, both of which can
indirectly indicate the fluidity of the droplets. The WT and NLS mutant FUS display
fast and near complete recovery of fluorescence, whereas R mutants exhibit slower
and incomplete recovery (Fig 3-8D). Remarkably, G mutants display much slower and
severely dampened overall recovery of fluorescence even compared to the R mutants.
The mobile fraction at 3hr for different mutants depict these difference more clearly
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Figure 3-8. (A) Droplets formed by 1µM FUS variants cleaved by tobacco etch virus
(TEV) protease in the presence of 1microM U40 and 10 nM Cy3-labeled U40 RNA. The
scale bar indicates 20µm (B) Area of WT and FUS mutant droplets plotted over time (C)
and taken at the 3hr time point. (D) FRAP curves for FUS variants (E) and the mobile
fraction after 3hr. All error bars are SEM. (F) Concentration dependent droplet formation
for the WT, R244C, R521C, and R521G. (G) Plot showing the total area covered by the
droplets over concentration to calculate Csat. (H) Quantification of Csaturation results
obtained in (F)
(Fig 3-8E).
To further characterize the R mutants, we measured the saturation concentration
(Csat) [71] of R244C, R521C, and R521G and compared it with that of the WT
by performing a condensation assay at varying protein concentrations depicted in
Figure 3-8F. To calculate Csat we plotted the total covered area by the droplets
at varying protein concentrations. The linear region of the plot was fitted and its
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intersection with the x-axis represents the Csat (Fig 3-8G and H). The results clearly
show a substantially lower Csat for all three R mutants tested, confirming the elevated
aggregation propensity for the R mutants (Fig 3-8F–H).
Building on the results observed above, we hypothesize that the R mutants make a
defective contact with RNA, forming an altered configuration that leads to a higher
aggregation propensity and supports growth to aberrantly large condensates that
are less fluid. Unexpectedly, G mutants form highly aggregated condensates, likely
from rapid aging, despite displaying more WT-like interactions with RNA in EMSA
and smFRET assays and forming condensates comparable in size with those of FUS-
WT than the R mutants. Together, our results point toward disparate molecular
mechanisms underlying pathogenesis, resulting from selective loss of arginine versus
glycine.
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Disassembly of aberrant FUS-RNA complexes in
ALS-linked FUS mutants
Protein quality control (PQS) is crucial for the cells to survive. PQS refers to
a combination of mechanisms and regulations that ensure translated proteins are
functional and not toxic for the cell such as the disaggregating and degrading misfolded
proteins. ALS patients can live many years despite having mutated proteins which
indicates there must be some sort of quality control in the cells for these proteins [88].
In this section, we are interested in understanding the disassembly of FUS droplets
and possibly identifying factors to reverse the aggregation observed in FUS mutants.
Several proteins including Kapβ2 and Ubiquilin have been proposed to directly interact
with FUS and help maintain FUS droplets and have possible disassembly roles.
Kapβ2 dissolves FUS droplets effectively
A protein that controls the formation of FUS droplets and aggregates is Karyopherinβ2
(Kapβ2). Kapβ2 is a Ran-sensitive transportin protein that binds tightly to the PY-
NLS of FUS transporting it from the cytoplasm to the nucleus [95, 121, 122]. Kapβ2
is also the only known high-affinity partner for FUS that has been characterized [122].
Recent studies have reported that Kapβ2 plays a critical role in disaggregating FUS
and FUS-related protein aggregates providing a promising new therapeutic avenue
[123–126]. It is reported to primarily high-affinity contacts with the FUS PY-NLS
domain and weaker secondary contacts with other regions of FUS [126].
Previous literature mainly focused on the disaggregation activity of Kapβ2 in the
context of FUS condensates without RNA, but we were interested in investigating its
effect on FUS condensates in the presence of RNA. We wanted to know if Kapβ2 is
able to reverse the defective molecular signatures of mutant FUS, including loss of the
dynamic interaction with RNA, the increased aggregation propensity of the FUS:RNA
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complex, and the formation of larger, non-spherical FUS-RNA condensates?
Figure 3-9. (A) Droplets formed using 1µM R244C in the absence and presence of 0.5
and 1µM Kapβ2 over time. Quantification of the (B) size and (C) circularity of each
droplet condition over time. (D) FRAP curves of the droplets at 3 h All error bars are
SEM. (E) Effect of Kapβ2 on WT-FUS and G156E droplets.
To study the effect of Kapβ2 at the condensate scale, we performed phase separation
assay in which we formed R244C droplets with equimolar RNA in the absence and
presence of Kapβ2 (Fig 3-9A). As previously seen in Figure ??, R244C-RNA forms
large, aberrantly shaped condensates without Kapβ2. In the presence of 0.5–1µM
Kapβ2, the condensates were significantly smaller in size and more circular in shape
(Fig 3-9B and C). Interestingly, FRAP analysis showed that the undissolved portions
of R244C droplets in the presence of Kapβ2 are just as solid-like as the R244C
condensates without Kapβ2 (Fig 3-9D) suggesting that Kapβ2 is not able to dissolve
heavily aggregated condensates completely. This is in contrast to the WT condensates,
which dissolved completely when mixed with Kapβ2 and G156E condensates which
substantially reduced the droplet size but left behind fiber-like structures (Fig 3-9E).
The small but non-fluid condensates of R244C and G156E suggest that Kapβ2 does
dissolve mutant RNP condensates but is unable to fully resolve a solid-like component
of the mutant droplets.
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Kapβ2 rescues FUS mutants altered RNA interactions
Next, we wanted to see if Kapβ2 is able to reverse the static RNA interactions of
R244C and G156E? First, we conducted the EMSA analysis for R244C (500nM)
and pdU50 RNA (1nM) mixed with increasing concentrations of Kapβ2 (Fig 3-10A).
We confirmed that Kapb2 does not bind RNA without FUS (Fig 3-10A, second
lane). The aggregated band of R244C-bound pdU50 persists in the presence of sub
equimolar concentrations of Kapβ2. At equimolar concentration, the aggregated band
was substantially diminished and completely abolished even higher concentrations of
Kapβ2, indicating clear FUS-RNA disaggregation activity of Kapβ2. The same EMSA
assay performed with the most aggregation-prone G mutant, G156E, also showed a
similar Kapb2 dissolution effect (Fig 3-10C). This result reveals that Kapb2 selectively
dissolves aggregated FUS bound to RNA without disrupting FUS-RNA interaction.
We will address this point in more detail in the following sections.
To investigate the nature of the RNA interactions in the presence of Kapβ2, we tested
the R244C-RNA interaction using our smFRET assay with and without Kapβ2 (Fig 3-
10B). The high FRET peak for 500nM R244C was accompanied by predominantly static
smFRET traces. Strikingly, addition of equimolar Kapβ2 induced the appearance a
broad mid-FRET peak (mid-FRET population change from 24% to 69%) accompanied
by highly dynamic FRET fluctuations in a significant fraction of smFRET traces,
suggesting recovery of WT-like RNA interactions by Kapβ2 (Fig 3-10B). Consistently,
G156E showed a similar increase in dynamics upon addition of Kapβ2 (mid-FRET
population shift from 14% to 60%) as evident by Figure 3-10D. To compare the
changes in dynamic RNA interactions, we measured and plotted the dynamic fraction
observed in smFRET traces in the form of a violin plot shown in Figure 3-10E. The
plot clearly shows the population shift from more static traces (bottom heavy; close
to 0) in the absence of Kapβ2 to a wider spread with a median closer to 1 in the
presence of Kapβ2.
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Figure 3-10. (A) EMSA gel of 500nM R244C incubated with varying concentrations of
Kapβ2 (0–1000nM).(B) Representative FRET histograms and traces for 500nM R244C
in the absence and presence of equimolar concentrations of Kapβ2. (C) EMSA gel of
500nM G156E incubated with varying concentrations of Kapβ2.(D) Representative FRET
histograms and traces for 500nM G156E with and without equimolar concentrations of
Kapβ2.(E) Violin plot of dynamic fractions observed in smFRET traces in B and D.
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Here we demonstrated that Kapβ2 can reverse FUS mutants behavioral defects by
dissolving protein-RNA aggregates while enabling proper and dynamic FUS-RNA
interaction (via EMSA and smFRET). Furthermore, addition of Kapβ2 to mutant
RNP condensates revealed that these may be heterogeneous structures consisting of
one component that is capable of interacting with Kapβ2 and another component
that is uncooperative to Kapβ2’s activity.
Kapβ2 does not engage with the RNA bound FUS
Because Kapβ2 does not interact with RNA by itself, such rescue can only arise
from Kapβ2 interacting with FUS to directly dissolve aggregates, which is sufficient
for recovering the WT-like dynamics of the FUS-RNA interaction. In the previous
section, we observed evidence suggesting that Kapβ2 might not interact with the
RNA-bound FUS. We proposed two possible scenarios for how Kapβ2 dissolves mutant
FUS aggregates illustrated in Figure 3-11. In the first scenario, Kapβ2 disassembles all
FUS-FUS and FUS-RNA complexes. In the second scenario, Kapβ2 only dismantles
the FUS-FUS aggregates and leaves the FUS-RNA complex (potentially C2 given
the high concentration) intact. These bound FUS-RNA complexes then will have the
chance to interact properly.
We tested these hypotheses using our single molecule assay with immobilized pdU50.
Logically, if scenario I is correct, removal of all components after they interacted
with the RNA for some time (Kapβ2 and R244C from the single molecule surface by
buffer washing) should recover the RNA only FRET histogram. Figure 3-12A shows
otherwise. Kapβ2 is able to recover the RNA interaction of R244C when added in an
equimolar concentration, but after free molecules are washed away, the majority of
the molecules exhibit high-FRET consistent the FUS-RNA complex. Further evidence
supporting scenario II comes from the EMSA (Fig 3-12B) in which R244C and RNA
are mixed with varying concentrations of Kapβ2. In this gel, Kapβ2 is labeled with
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Figure 3-11. Illustration depicting possible mechanisms in which Kapβ2 is able to rescue
altered RNA interactions in mutants.
Cy3 (green), RNA is labeled with Cy5 (red), and R244C is labeled with Alexa-488
(blue). The Kapβ2 and the C2 or C1 band run at different locations. However a
population of FUS-Kapβ2 emerges at the top of the gel replacing the FUS aggregates
in the absence of Kapβ2.
These data together support scenario II (Fig 3-11) is more likely to be Kapβ2’s mode
of action. Kapβ2 takes away the aggregated population of FUS that are not bound
directly to the RNA and reduces the RNA complex to its core dimer form which than
is able to freely interact with the RNA inducing dynamics. Most certainly, further
experiments are needed to reveal the exact role of Kapβ2 by labeling it can reveal
how it rescues mutant dynamic in single molecule and sheds light of disaggregating
droplets.
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Figure 3-12. (A) FRET histograms and corresponding representative traces for R244C
with and without Kapβ2 and after buffer wash. (B) EMSA with labeled R244C (blue),
Kapβ2 (green), and pdU50 RNA (red). Kapβ2 is added in varying concentration (0-1µM).
The magenta and orange boxes show intensity profile of all three channels for 500nM
R244C with RNA and 500nM R244C+1µM Kapβ2 with RNA, respectively.
UB2 changes R244C-RNA interaction pattern
As mentioned earlier, one of the many proteins that is known to interact with FUS and
regulate its role in the stress granule is Ubiqulin 2 (UB2). UB2 is a protein known to
act as a proteasome chaperone redirecting misfolded proteins [127, 128]. UB2 contains
a ubiquitin-like domain at the N-terminus, a stretch of PXX amino acid repeats, and
a ubiquitin-associated domain at its C-terminus [129–131]. Mutations in the UBQLN2
gene has been shown to be linked to ALS [132]. UB2 has been shown to regulate FUS
in stress granules in vivo [133], therefore, we asked if UB2 could reverse the altered
RNA interactions of FUS mutants particularly R244C.
To test this possibility, we used smFRET Cy3-Cy5 labeled pdU50 immobilized on the
surface and monitored the RNA conformation as shown in Figure 3-13. The presence
of 1µM R244C shifts the FRET histogram from a sharp distribution of static low
FRET (0.2) to two populations with mid and high-FRET. More than 85% of the
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molecules in these populations exhibit static RNA interaction (Fig 3-13C; 0min) which
is expected as seen in Figure 3-2.
Figure 3-13. (A) FRET histograms for different conditions and UB2 variants with
corresponding representative traces showing the FRET fluctuation (B) Dwell time analysis
for the time between two consecutive FRET fluctuations at 5, 20, 40min after addition of
WT UB2. The data was fitted to a single exponential decay and the decay rat (τ) and
STD is reported for each condition. (C) Percentage of single molecules with dynamic vs.
static smFRET ratios.
In the presence of 4µM of WT-UB2 mixed with 1µM R244C-FUS, we observe a
time dependent shift is the FRET histogram toward high FRET values. At this
concentration, the majority of molecules are non static. At 5 minutes after addition,
the molecules exhibit a very slow transition from high/mid-FRET static to lower
values and so on. After 20 or 40 minutes, not only the number of dynamic traces but
the frequency of dynamic FRET fluctuations increased (Fig 3-13A). We measured the
time between two consecutive FRET changes (transition from high to mid) for each
trace. Next we plotted these time values for 5, 20, and 40 minutes after addition of
WT-UB2 in the form of a histogram as displayed in Figure 3-13B. The histograms
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were then fitted using a single exponential decay and the decay constant (τ) and its
error was reported. As seen from the numbers in Figure 3-13B, the time between
fluctuations drops from 11.1±1.6s at 5min to 1.08±0.04s at 40min. More convincingly,
the fraction of molecules that exhibit dynamic traces, drastically increased in the
presence of WT-UB2. This increase continued with increasing incubation time went.
Interestingly, in contrast with the WT-UB2, two UB2 mutations in the PXX region,
P497H and P506T, exhibit reduced effects compared to WT-UB2. As seen in Figure
3-13A (bottom two), the traces in the presence of 4µM P497H and P506T show high
levels of static interactions (∼90% and ∼70% respectively according to Fig 3-13C)
comparable to R244C-FUS alone. This failure to affect FUS–RNA complex assembly
dynamics indicates a partial compromise of UB2 function conferred by these UB2
ALS-linked mutations.
WT-UB2 regulates the size of R244C-FUS droplets
The dynamics of RNA and RNA binding protein will directly impact LLPS of those
proteins [110, 134]. We wanted to know whether WT-UB2 will affect the phase
separated droplets formed by R244C-FUS given that WT-UB2 impacts the dynamics
of it interaction with RNA. Earlier we showed that R244C-FUS forms large irregular
droplets which do not recover as robustly as the WT-FUS when bleached (Fig ??A).
We formed droplets by cleaving off the MBP tag of 1µM R244C-FUS mixed with
1µM U40 RNA in the presence and absence of 4µM WT-UB2 and monitored the
droplets over 20 hours (Fig 3-14A). In the case of R244C-FUS alone, as the mixture
ages, the droplets grow into large and irregularly shaped condensates, as expected.
In contrast, the droplets formed in presence of the WT-UB2 form smaller and more
circular droplets (Fig 3-14B-D).
In terms of size, addition of WT-UB2 reduced the average droplet size after 20 hours
from 8.03±0.25µm2 without WT-UB2 to 2.97±0.06µm2 with WT-UB2. This aligns
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Figure 3-14. Phase separation of (A) 1µM R244C-FUS alone and (B) with 4µM WT-UB2
over 20hrs. All conditions are with 1µM U40 RNA and doped with 10nM Cy3-U40 RNA.
The scale on the image is 20µm. (B-D) Quantification over 20 hrs measuring (B) number
of droplets, (C) circularity, and (D) droplet areas for R244C in the absence (Red) and
presence (Cyan) of WT-UB2. The error bars are SEM.
with findings that UB2 can regulate FUS condensates in stress granules in vivo [133].
Moreover, WT-UB2 has an effect on the shape of the droplets increasing the average
circularity from 0.87 to 0.96 where 1 is a perfect circle. The non-spherical irregular
droplets observed in R244C-FUS may represent the transition from the reversible
liquid-like, phase-separated state of FUS to a more stable, solid state of FUS that
seems to be reversed with the introduction of WT-UB2. This reduction is size and
increased circularity (Fig 3-14C) led to higher number of droplets per field of view as
seen in Figure 3-14A and B.
All together, these data suggest UB2 is capable of preventing the gelification of the
R244C-FUS variant and recover its altered RNA interaction to a great extent. This is
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in agreement with the negative regulatory role of UB2 in stress granules.
Discussion and conclusion
In this chapter, we examined 14 variants of FUS proteins (12 ALS/FTD-linked FUS
mutations with two control mutations for R224C variant). We investigated the RNA
interaction and droplet properties of these variants in comparison with WT FUS to
understand how disease mutations diverge from WT. We found that despite the severe
pathogenic nature of the two NLS mutants (R495X and P525L), they are comparable
to WT FUS in RNA binding, including multimer-induced dynamics, and forming
normal-sized fluidic condensates (Fig 3-6, 3-7, and 3-8). This result reiterates the
significance of the NLS domain, when mutated, can disrupt nuclear transport leading
to accumulation in cytoplasm and advanced disease onset [123–126]. Our results
suggest that R mutants interact statically with RNA arising from the formation of a
defective C1 that gives rise to aggregated RNP complexes and large and non-circular
condensate. The two control mutants (R244K and R244A) strongly suggest that
R244C’s molecular defects are due to the loss of arginine.
At first glance, our results may appear to contradict a recently published report [71]
that defined the role of arginines, which were classified as "stickers" in increasing the
propensity for phase separation, whereas loss of arginine in our results increased the
aggregation potential. However, there are two major differences; 1) they mutated
multiple arginines simultaneously that increased the Csat (the concentration at which
phase separation occurs); and 2) the study was conducted in the absence of RNA.
Here we investigated the effect of a single arginine mutation in the presence of RNA.
Altogether, the overall high density of arginine is critical for promoting protein
condensation, whereas individual arginines may be important for establishing proper
contacts with RNA allowing the formation of fluid condensates.
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Figure 3-15. Graphical summary showing clustering of different classes of FUS variants
based on their RNA interaction in single molecule and fluidity measured using FRAP.
Kapβ2 and UB2 can reverse the effects of the mutations and rescue WT-like behaviors.
However, the G mutants exhibit a unique pattern of WT-like dynamic interaction with
RNA on a single-molecule level but extreme loss of fluidity in condensates. Unlike
the R mutant case, the characteristic of glycine mutants are in agreement with Wang
et. al. [71] finding that glycines are spacers controlling the fluidity of the formed
droplets. Our findings shows that removing even a single glycine can drastically affect
the fluidity of FUS-RNA condensates. Single molecule data suggests that G mutations
don’t perturb the RNA interaction as much as it affects the fluidity of the formed
condensates.
The solid-like condensates may also accelerate disease progression and dampen dis-
aggregation potential by other proteins. Our work showed that ubiquillin-2, which
physically associates with FUS in cells, is capable of relaxing static mutant FUS-RNA
interactions and promoting fluid condensate formation (Fig 3-13 and 3-14) [133].
Moreover, recent studies showing that Kapβ2 acts as a protein disaggregase [123–126]
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have brought attention to potential applications of such proteins as treatment for
incurable neurodegenerative diseases. Our findings (Fig 3-10 and 3-9) demonstrate
that Kapβ2 rescues the mutants’ defective interactions with RNA by reviving the
dynamic FUS-RNA interaction in both R and G mutants. We also observed that
Kapβ2 cannot interact with RNA-bound FUS, hence, rescuing the WT-like dynamics
through reducing the aggregated states enabling FUS to interact with RNA in a
normal manner. Our future efforts will be directed to elucidating the mechanistic
basis of the Kapβ2 rescue effect on FUS-RNA interaction. It will also be critical to
probe FUS variants with non-ALS/FTD-linked mutations to see whether the molecular
phenotypes that we observed are due to the specific positions of R and G or simply





All the plasmids (WT and mutants) are ordered from GenScript. Detailed information
about the plasmids are found in Niaki et al. [82]. After transforming the plasmid in
E. Coli BL21(DE3) cells, a glycerol stock (50% glycerol) was made and kept at -80°C
for storage and regrowing cells. Next a starter culture was inoculated directly from
the -80°C stab. The starter culture was about 5mL LB with 50µg/ml kanamycin and
incubated overnight at 37°C overnight with shaking (200 rpm). The next day, cells
were grown in a 0.5L flask containing autoclaved LB at 37°C until reaching OD of
0.3-0.4 then induced with 0.25mM IPTG for 2hr at 30°C. After induction, cells were
pelleted at 4000rpm for 10min and kept in -80°C.
The purification was done using an using an AKTA pure 25M FPLC system (GE).
To lyse, the cells were re-suspended in lysis buffer (Table 4.1) and sonicated with 8s
ON-OFF cycles for 6min. The lysed cells were pelleted using the Beckman centrifuge
at 14,000rpm for 20min. The supernatant was filtered using 0.22µm filters and loaded
on the FPLC’s 50mL super loop. The column used in this method is a HisTrapFM
Crude 5mL column. After elution, 25-30% glycerol was added to the protein and
stored @ 4°C. The FPLC protocol is as follows:
1. Column wash with MQ water @ 4ml/ min for 10 column volumes (CV)
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2. Equilibration with binding buffer @ 4ml/ min for 10 CV
3. Sample application using binding buffer 0.3ml/ min
4. Column wash 4ml/ min for 10 CV
5. Gradient eluction from 0-80% eluction buffer over 8 CV @ 0.3ml/ min
6. Column wash with elution buffer for 2 CV @ 0.3ml/ min then column wash with
water for 10 CV @ 4ml/ min
7. Equilibration with 20% EtOH for proper storage @ 0.3ml/ min
Table 4.1. Buffer composition for FUS purification
Reagents Binding Buffer Lysis Buffer Elution BufferAmount [Final] Amount [Final] Amount [Final]
Urea 60g 1M - - - -
KCl 74.5g 1M - - - -
1M Tris
pH 7.5
50mL 50mM - - - -
Imidazole 0.68g 10mM - - 3.4g 500mM
50% (vol.)
Glycerol
100mL 5% - - - -
Binding
Buffer
- - 25mL 1x 100mL 1X
βME 120µl 1.5mM - - - -
Protease
inhibitor
- - 0.5 tablet - - -
NP-40 - - 250µl 1% - -
RNase - - 100µl - - -
MQ Water up to 1L - - - - -
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RNA sample preparation
The following ssRNAs are used in all the experiments and were purchased from IDT:
• 18-mer: 5′-biotin-UGG CGA CGG CAG CGA GGC-3′-amine
• (U10-70)18-mer: 5′-amine-(U10-70)-GCC UCG CUG CCG UCG CCA-3′
• U40: 5′-(U40)-3′-amine
Amino modified RNA strands were labeled with Cy5 or Cy3 using the common NHS-
ester-amine labeling scheme. The partial duplexes were generated by annealing the
18-mer strand and polyU strand. To achieve efficient annealing, RNA strands were
mixed in T50 buffer (50mM NaCl and 10mM Tris), heated to 85°C for 2min and
slowly cooled down to room temperature (1°C/ min).
single molecule FRET (smFRET)
PEG Slide Preparation
Passivated PEG slides were used for all the performed single molecule experiments.
In brief, quartz slides and glass coverslips were thoroughly washed in Methanol and
Acetone. Next, slides were sonicated in 1M KOH for 30min and flamed for 30s. The
slides and coverslips were coated with aminosilane for 20min, then treated with a
mixture of 98% mPEG (m-PEG-5000, Laysan Bio, Inc.) and 2% biotin PEG (biotin-
PEG-5000, Laysan Bio, Inc) over night. The slides and coverslips were then washed
a dried using nitrogen gas and stored in -20°C. More detailed protocol and slide
assembly instructions are described in [135].
smFRET and PIFE measurements
All the experiments were performed at room temperature and using a home-built
prism-type TIRF microscope. Cy3/Cy5 FRET pair labeled RNA or the Cy3 labeled
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PIFE substrates prepared, as described in RNA sample preparation section, were
immobilized on PEG-passivated quartz slides via biotin-Neutravidin linkage. Next, the
protein was added to the slide at varying concentrations in imaging buffer containing
an oxygen scavenger system to stabilize fluorophores (20mM Tris-HCl, pH 7.5, 100mM
KCl, 0.5% glucose, 1mg/ml glucose oxidase, 1.8U/mL catalase, and 10mM trolox).
Movies were recorded from different regions of the surface using smCamera package
which then was converted into time traces using custom made IDL scripts.
In order to do flow experiments, small reservoirs made of the top portion of pipette tips
were installed on the PEG slides. In these experiments, data acquisition commenced
before the sample was introduced. After 6-10s, the sample was withdrawn from the
reservoir into the slide chamber using an automated pump (40µl of sample at the rate
of 1mL/min).
EGFP photobleaching
Annealed pdU50 RNA only labeled with Cy5 on the 18-mer strand was immobilized
on the surface of the PEG slide. WT FUS with EGFP tag was introduced at
varying concentrations (2.5-50nM) with buffer containing 20mM Tris and 100mM KCl.
Data was acquired from different regions of the slide while the sample was excited
with a 488nm laser to bleach the EGFP molecules. The movies were converted to
intensity-time traces similar to the normal smFRET experiments. The traces were
then categorized by the number of photobleaching steps.
To account for the pre-dimerization of EGFP, 5nM WT FUS with EGFP tag was
added to the surface of the slide with 10nM anti-GFP antibody immobilized on it
for 15min then washed an bleached using a 488nm laser. The photobleaching steps




All traces were visualized and analyzed using customize MATLAB scripts. Histograms
were generated from thousands of molecules. The donor only peak was cropped
out using Cy5 intensity cutoffs. categorizing the time traces was done manually
by assigning a category (dynamic, static, etc.) to each trace and calculating the
relative representation of that pattern. For dwell time analysis, the time between
two consecutive FRET events was measured as part of the MATLAB script then a
histogram of all the time values was plotted and fitted to a single exponential decay
function. The decay constant was reported as the dwell time for each condition.
Similar quantification was performed to measure the binding time in different PIFE
constructs.
To quantify the different mutant smRET traces, the fractions of time spent in the
dynamic state (non-static high FRET) over the meaningful observation time (before
photobleaching) was measured for more than 150 molecules. Then, the fraction values
(from 0 to 1) were plotted as violin plots via a MATLAB script.
First step in analyzing the flow experiment was collecting all the meaningful traces.
Categorizing the behavior was done similar to normal FRET traces. At any timepoint
along the trace, a normalized FRET histogram was generated. A series of these
histograms were combined to make a heatmap of all the traces visualizing the initial





The purified protein is stored in a buffer containing 1M KCl and 1M Urea which was
buffer exchanged using 20mM sodium phosphate pH 7.5 through a 50kDa Amicon
Millipore filter. The filter was rinsed using centrifugation at 10,000rpm for 2min
with buffer only before addition of the protein. After buffer exchange, the droplet
reaction was prepared by mixing 1µM FUS protein (this amount varies depending on
the experiment), 1µM U40 RNA (varies), 10nM Cy3 labeled U40 RNA, 1X cleavage
buffer described in Table 4.2, TEV protease (0.1µl per 0.3µg of protein), and RNase
free water up to 200µl. The solution was then added to the surface of an 8-well Nunc
Lab-Tek chambered coverglass.
Table 4.2. 10X cleavage buffer (100mL)
Reagent Amount [Final]
1M Tris, pH 7.5 50µl 500mM
5M NaCl 20µl 1M
0.5M EDTA 2µl 10mM
1M DTT 1µl 10mM
R-free Water 27µl -
Imaging & FRAP
The prepared sample was imaged over time using a Nikon Ti Eclipse microscope
with a 100x oil immersion objective excited at 555nm (LED light source) with a Cy3
emission filter (Cy3 channel). The images were captured by an EMCCD Andor camera
spanning an area of 133.3µm by 133.3µm. Similar procedure was done for the Csat
experiments. The fluorescence recovery after photobleaching (FRAP) measurements
were done using Nikon FRAP module bleaching the sample by a 50mW laser att 405nm
and a Brucker galvano mirror scanner. Multiple granules were bleached completely in
the same field of view (ROI of 10-20 pixels in diameter) for 5ms per pixel using 100%
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laser intensity. Acquiring data for the recovery resumed immediately after bleaching
using Cy3 channel of the microscope at every 3s for the first 2min and every 10s for
another 8min.
Analysis
In order to quantify droplet formation and growth (for all droplet experiments), we
used the intensity-based cell counting macro from NIS-Element AR software provided
by Nikon Inc., extracting the number and size distribution of the droplets at each
condition and time point. The mean ± SEM was calculated for each condition and
variable to represent the population. The data were plotted by Origin Pro 8.5.
Analyzing the FRAP data starts with converting the .nd2 files to .tif stacks using
ImageJ. Once converted, the data videos were analyzed using a custom made MATLAB
script where the bleached, reference, and background ROIs are chosen. The average
intensities form each bleached ROI were recorded over each and corrected for the
overall photobleaching using the equation below:
Icorr =
I(t) − B
Iref (t) − B
where, Icorr(t) is the corrected mean intensity of the ROI and a given time, B is the
average background (no droplet region), and Iref(t) is the mean reference droplet
(unbleached) intensity at t. The corrected intensities are then normalized using the





Elctrophoresis Mobility Shift Assays (EMSA)
This method is used to study the different complexes formed by FUS bound to variety
of RNAs. All the reactions are in 1X binding buffer described in Table 4.3.
Table 4.3. Components of the 10X binding buffer
Reagents Amount [Final]
1M Tris, pH 7.5 25µl 500mM
1M MgCl2 1µl 20mM
βME 3.6µl 1M
20mg/ml BSA 2.5µl 1mg/ml
3.2M KCl 15.2µl 1M
MQ Water 2.7µl -
After making the binding buffer, reactions are prepared according to Table 4.4 and
incubated in dark at room temperature for 30min. 1x loading dye is added to each
reaction and then loaded on a 6% DNA retardation gel. The gel runs at 150V for about
an hour in 0.5X TBE buffer. For visualization, the gel is imaged using a Typhoon
imager using Cy3 and Cy5 laser. Quantification is done using ImageQuant. Intensities
of each band was normalized based on the total intensity of each lane after background
subtraction.
Table 4.4. Typical EMSA reaction reagents
Reagents Amount [Final]
Protein varies varies
10x Binding Buffer 1µl 1x
10nM RNA 1µl 1nM
R-free water to 10µl -
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